

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number  
**WO 01/10456 A2**

(51) International Patent Classification<sup>7</sup>: A61K 38/06,  
C12Q 1/70, C07K 5/08, A61P 31/00, G01N 33/50, 33/569

(21) International Application Number: PCT/IB00/00961

(22) International Filing Date: 29 June 2000 (29.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/370,368 9 August 1999 (09.08.1999) US

(71) Applicant: TRIPEP AB [SE/SE]; Halsovägen 7, S-141 57  
Huddinge (SE).

(72) Inventor: VAHLNE, Anders; Wendelsväg 4, S-436 50  
Hovås (SE).

(74) Agent: HERMANN, Gerhard; Vossius & Partner,  
Siebertstr. 4, D-81675 Munich (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility  
model), DK, DK (utility model), DM, DZ, EE, EE (utility  
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility  
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,  
TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished  
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF



(57) Abstract: The discovery of peptides in amide form that inhibit viral infection, including human immunodeficiency virus (HIV) infection is disclosed. Methods of use of peptides are also disclosed including use in medicaments for the treatment and prevention of viral infection, such as HIV infection.



WO 01/10456 A2

**PEPTIDES THAT BLOCK VIRAL INFECTIVITY  
AND METHODS OF USE THEREOF**

**FIELD OF THE INVENTION**

5           The present invention is related to the discovery of peptides that inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising various small peptides are disclosed for use in the treatment and prevention of viral infection, such as HIV infection.

**BACKGROUND OF THE INVENTION**

10           All viruses are composed of a protein shell surrounding a nucleic acid containing core. The protein shell directly surrounding the viral nucleic acid is called a capsid, whereas, the complete protein-nucleic acid complex having both the capsid and the nucleic acid is called a nucleocapsid. Arenaviruses, rotaviruses, orbiviruses, retroviruses (including lentiviruses), papillomaviruses, adenoviruses, herpesviruses, paramyxovirus, myxovirus, and hepadnaviruses all exhibit these general structural features. (Virology, Fields ed., third edition, Lippencott-Raven publishers, pp 1513, 1645, 1778, 2047, 2113, 2221, and 2717 (1996)).

15           The capsid is composed of many subunits (capsomeres) and capsomeres are formed from several homo or hetero-polymers of protein. The noncovalent bonds between capsomeres in a viral assembly are of the same sort that stabilize a folded protein domain. The interface between two subunits can look very much like a single domain, with amino acid side chains tightly packed against one another. A common feature to most of the virus structures analyzed is the way in which a polypeptide chain from one capsomere can extend under or over domains of neighboring  
20           capsomeres. These extended polypeptide arms intertwine with other polypeptide arms and help to stabilize the capsid by initiating hydrophobic interactions, hydrogen bonding, and salt bridges. Contacts between individual capsomeres, and for some viruses also contacts with core proteins, determine the overall capsid structure and if a number of identical capsomeres are involved, repeated contacts occur and the resulting structure is symmetrical. (Virology, Fields ed., third edition, Lippencott-Raven publishers, p 62 (1996)).

25           Some simple viruses form spontaneously from their dissociated components while others require enzyme-catalyzed modifications of the capsomeres to trigger assembly. Viral self assembly is driven by the stability of the interactions between protein subunits under conditions that favor association. More complex viruses are often constructed from subassemblies that have undergone self assembly processes. (Virology, Fields ed., third edition, Lippencott-Raven publishers, pp 62, 70, 1646 and 1888 (1996)). Although the capsids of many viruses differ in  
30           protein composition, a general viral structural design has evolved characterized by polymerized capsomeres that, in turn, are composed of several homo- or hetero- polymers of protein.

          HIV is the name given to a lentivirus that infects humans and that causes acquired immuno-deficiency syndrome (AIDS). The lentivirus isolates from humans are grouped into one of two types (HIV-1 and HIV-2) on the basis of serologic properties and sequence analysis of molecularly cloned viral genomes. Genetically distinct  
35           lentiviruses have been obtained from several non-human primate species including African green monkeys, sooty

magabeys, mandrills, chimpanzees, and sykes. Collectively, the lentivirus isolates from non-human primates are called SIV. Sequence analysis reveals that the genomes of some SIV strains and HIV-1 and HIV-2 strains exhibit a high degree of homology. Further, electron microscopy reveals that the ultrastructure of HIV and SIV are similar in that both have virions about 110nm in diameter with a cone-shaped nucleocapsid surrounded by a lipid bilayer membrane that contains envelope glycoprotein spikes. (*Virology*, Fields ed., third edition, Lippencott-Raven publishers, pp 1882-1883 (1996)).

HIV is a complex retrovirus containing at least seven genes. The viral structural genes, designated *gag*, *pol*, and *env*, respectively code for the viral core proteins, reverse transcriptase, and the viral glycoproteins of the viral envelope. The remaining HIV genes are accessory genes involved in viral replication. The *gag* and *env* genes encode polyproteins, i.e., the proteins synthesized from each of these genes are post-translationally cleaved into several smaller proteins.

Although the overall shape of HIV and SIV virions is spherical, the nucleocapsid is asymmetrical having a long dimension of about 100nm, a wide free end about 40-60nm, and a narrow end about 20nm in width. The nucleocapsid within each mature virion is composed of two molecules of the viral single-stranded RNA genome encapsulated by proteins proteolytically processed from the Gag precursor polypeptide. Cleavage of the *gag* gene polyprotein Pr55<sup>gag</sup> by a viral coded protease (PR) produces mature capsid proteins. These *gag* gene products are the matrix protein (p17), that is thought to be located between the nucleocapsid and the virion envelope; the major capsid protein (p24), that forms the capsid shell; and the nucleocapsid protein (p9), that binds to the viral RNA genome. This proteolytic processing in infected cells is linked to virion morphogenesis. (*Virology*, Fields ed., third edition, Lippencott-Raven publishers, pp 1886-1887 (1996)).

The major capsid protein p24 (also called CA) contains about 240 amino acids and exhibits a molecular weight of 24-27 kD. The protein p24 self-associates to form dimers and oligomeric complexes as large as dodecamers. Genetic studies with mutations in the HIV-1 gag polyprotein have identified several functional domains in the p24 protein including the C terminal half of the molecule and a major homology region (MHR) spanning 20 amino acids that is conserved in the p24 proteins of diverse retroviruses. These mutations appear to affect precursor nucleocapsid assembly. (*Virology*, Fields ed., third edition, Lippencott-Raven publishers, pp 1888-1889 (1996)).

Since the discovery of HIV-1 as the etiologic agent of AIDS, significant progress has been made in understanding the mechanisms by which the virus causes disease. While many diagnostic tests have been developed, progress in HIV vaccine therapy has been slow largely due to the heterogeneous nature of the virus and the lack of suitable animal models. (See, e.g., Martin, *Nature*, 345:572-573 (1990)).

A variety of pharmaceutical agents have been used in attempts to treat AIDS. Many, if not all, of these drugs, however, create serious side effects that greatly limit their usefulness as therapeutic agents. HIV reverse transcriptase is one drug target because of its crucial role in viral replication. Several nucleoside derivatives have been found to inhibit HIV reverse transcriptase including azidothymidine (AZT, zidovudine\*). AZT causes serious side effects such that many patients cannot tolerate its administration. Other nucleoside analogs that inhibit HIV reverse

transcriptase have been found to cause greater side effects than AZT. Another drug target is the HIV protease (PR) crucial to virus development. PR is an aspartic protease and can be inhibited by synthetic compounds. (Richards, *FEBS Lett.*, 253:214-216 (1989)). Protease inhibitors inhibit the growth of HIV more effectively than reverse transcriptase inhibitors but prolonged therapy has been associated with metabolic diseases such as lipodystrophy, hyperlipidemia, and insulin resistance.

Additionally, HIV quickly develops resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors and protease inhibitors. This resistance can also spread between patients. Studies have shown, for example, that one tenth of the individuals recently infected by HIV already have developed resistance to AZT, probably because they were infected by a person that at the time of transmission carried a virus that was resistant to AZT.

It would be useful in the treatment and prevention of viral infections, including HIV and SIV, to have specific and selective therapeutic agents that cause few, if any, side effects.

#### SUMMARY OF THE INVENTION

The present invention is related to small peptides (two to ten amino acids in length) that inhibit viral infectivity. An intact capsid structure is of vital importance for the infectivity of a virion. A way to disrupt assembly of capsid protein macromolecules, that for their infectivity are dependent on di-, tri-, tetra-, or poly-merization, is to construct small molecules that affect such protein-protein interactions. It was discovered that small peptides with their carboxyl terminus hydroxyl group replaced with an amide group have such an inhibiting effect on capsid-protein interactions. Thus, aspects of the present invention relate to modified small peptides that effect viral capsid assembly.

In desirable embodiments, the short peptides bind to a protein that is involved in capsomere organization and capsid assembly of HIV-1, HIV-2, and SIV and thereby inhibit and/or prevent proper capsid assembly and, thus, viral infection. The small peptides Gly-Pro-Gly-NH<sub>2</sub> (GPG-NH<sub>2</sub>), Gly-Lys-Gly-NH<sub>2</sub> (GKG-NH<sub>2</sub>), Cys-Gln-Gly-NH<sub>2</sub> (CQG-NH<sub>2</sub>), Arg-Gln-Gly-NH<sub>2</sub> (RQG-NH<sub>2</sub>), Lys-Gln-Gly-NH<sub>2</sub> (KQG-NH<sub>2</sub>), Ala-Leu-Gly-NH<sub>2</sub> (ALG-NH<sub>2</sub>), Gly-Val-Gly-NH<sub>2</sub> (GVG-NH<sub>2</sub>), Val-Gly-Gly-NH<sub>2</sub> (VGG-NH<sub>2</sub>), Ala-Ser-Gly-NH<sub>2</sub> (ASG-NH<sub>2</sub>), Ser-Leu-Gly-NH<sub>2</sub> (SLG-NH<sub>2</sub>), and Ser-Pro-Thr-NH<sub>2</sub> (SPT-NH<sub>2</sub>) are the preferred species. These small peptides and peptidomimetics resembling their structure (collectively referred to as "peptide agents") are used in a monomeric or multimeric form. The peptide agents of the present invention are suitable for therapeutic and prophylactic application in mammals, including man, suffering from viral infection.

In one embodiment, a composition for inhibiting viral replication in host cells infected with a virus has an effective amount of a peptide in amide form having the formula X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>-NH<sub>2</sub>, wherein X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>, and wherein said composition inhibits viral replication by interrupting viral capsid assembly. Desirably, X<sub>3</sub> of these peptides is glycine. Additionally, the compositions described above can include a peptide in amide form selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

In another related embodiment, the composition described above is a peptide in amide form that has the formula  $X_4X_5X_1X_2X_3\text{-NH}_2$ , wherein  $X_4$  and  $X_5$  are any amino acid and any one or two amino acids can be absent. This embodiment can be a tripeptide having the formula  $X_1X_2X_3$ , wherein the sequence is found in the amino acid sequence of the capsid protein of the virus.

5 In some embodiments, the compositions described above are joined to a support and in other embodiments, the compositions described above are incorporated into a pharmaceutical having a pharmaceutically acceptable carrier. For example, the peptide in amide form can have the formula Gly-Lys-Gly- $\text{NH}_2$  and can be joined to a support.

Further, the peptide in amide form can have a formula such as Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , or Ser-Leu-Gly- $\text{NH}_2$ . These peptides can also be joined to a support.

10 Methods of inhibiting HIV replication in a host cell are also embodiments. One approach, for example, involves administering to a cell an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly- $\text{NH}_2$ . Accordingly, the peptide above can be selected from the group consisting of peptides having the formula Gly-Lys-Gly- $\text{NH}_2$ , Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , Gly-Val-Gly- $\text{NH}_2$ , Val-Gly-Gly- $\text{NH}_2$ , Ala-Ser-Gly- $\text{NH}_2$ , Ser-Leu-Gly- $\text{NH}_2$ , and Ser-  
15 Pro-Thr- $\text{NH}_2$ . The method described above can further include the step of administering an antiviral treatment selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. The peptide used in the method above can be joined to a support or can be administered in a pharmaceutical comprising a pharmaceutically acceptable carrier.

20 In another embodiment, a composition for inhibiting HIV replication in host cells includes an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly- $\text{NH}_2$  and wherein said composition inhibits HIV replication by interrupting assembly of the capsid. Desirably,  $X_3$  is glycine in the peptides of this embodiment. Preferably, the peptide of this embodiment is selected from the group consisting of peptides having the formula Gly-Lys-Gly- $\text{NH}_2$ , Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-  
25 Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , Gly-Val-Gly- $\text{NH}_2$ , Val-Gly-Gly- $\text{NH}_2$ , Ala-Ser-Gly- $\text{NH}_2$ , Ser-Leu-Gly- $\text{NH}_2$ , and Ser-Pro-Thr- $\text{NH}_2$ . Additionally, the peptide in amide form, described above, can have the formula  $X_4X_5X_1X_2X_3\text{-NH}_2$ , wherein  $X_4$  and  $X_5$  are amino acids and wherein any one or two amino acids is absent. These compositions can have a tripeptide  $X_1X_2X_3$  that is found in the amino acid sequence of the capsid protein of HIV, for example. In some embodiments, these peptides are joined to a support and in other embodiments, these peptides are incorporated into a pharmaceutical comprising a pharmaceutically acceptable carrier.  
30

In another method, an approach to inhibit viral replication in host cells is provided, which involves administering to said cells an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly- $\text{NH}_2$ . In this method, the peptide can be selected from the group consisting of peptides having the formula Gly-Lys-Gly- $\text{NH}_2$ , Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-  
35 Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , Gly-Val-Gly- $\text{NH}_2$ , Val-Gly-Gly- $\text{NH}_2$ , Ala-Ser-Gly- $\text{NH}_2$ , Ser-Leu-Gly- $\text{NH}_2$ , and Ser-Pro-Thr- $\text{NH}_2$ .

This method can also include the step of administering an antiviral treatment selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. Further, the peptide used in this method can be joined to a support or can be administered in a pharmaceutical comprising a pharmaceutically acceptable carrier.

5 In another method, an approach for interrupting viral capsid assembly is provided. This approach involves contacting a cell with an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly- $\text{NH}_2$ . Desirably, the peptide used in this method is selected from the group consisting of peptides having the formula Gly-Lys-Gly- $\text{NH}_2$ , Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , Gly-Val-Gly- $\text{NH}_2$ , Val-Gly-Gly- $\text{NH}_2$ , Ala-Ser-Gly- $\text{NH}_2$ , Ser-Leu-Gly- $\text{NH}_2$ , and Ser-Pro-  
10 Thr- $\text{NH}_2$ . In some embodiments,  $X_3$  is glycine in the peptide used in this method.

In other embodiments, the method employs a peptide in amide form having the formula  $X_4X_5X_1X_2X_3\text{-NH}_2$ , wherein  $X_4$  and  $X_5$  are an amino acid and, wherein any one or two amino acids is absent. Still further, the method can involve the use of a tripeptide  $X_1X_2X_3$  that is found in the amino acid sequence of a protein of the virus.

Oftentimes the peptide of the method is joined to a support or is incorporated in a pharmaceutical.

15 Methods of identification of peptide agents are also provided. By one method, for example, a peptide agent for incorporation into an anti-viral pharmaceutical is identified by contacting a plurality of cells infected with a virus with an effective amount of a peptide agent, wherein said peptide is not Gly-Pro-Gly- $\text{NH}_2$ , analyzing the virus for incomplete capsid formation, and selecting the peptide agent that induces incomplete capsid formation. This method can involve an analysis of capsid formation that employs microscopy and the virus can be selected from the group  
20 consisting of HIV-1, HIV-2, and SIV. Further, the peptide agent identified can be selected from the group consisting of a tripeptide, an oligopeptide, and a peptidomimetic. For example, the peptide agent above can be selected from the group consisting of peptides having the formula Gly-Lys-Gly- $\text{NH}_2$ , Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , Gly-Val-Gly- $\text{NH}_2$ , Val-Gly-Gly- $\text{NH}_2$ , Ala-Ser-Gly- $\text{NH}_2$ , Ser-Leu-Gly- $\text{NH}_2$ , and Ser-Pro-Thr- $\text{NH}_2$ . In a preferred embodiment, the peptide agent used in the method above has an amino acid sequence that corresponds to an  
25 amino acid sequence of p24.

In another embodiment, a method for identifying a peptide agent that binds to a viral protein is provided, which involves providing a viral protein, contacting the viral protein with an effective amount of a peptide agent, wherein said peptide agent is not Gly-Pro-Gly- $\text{NH}_2$ , and detecting the formation of a complex comprising the viral protein and the peptide agent. As above, this method can involve the use of a viral protein that is from a virus  
30 selected from the group consisting of HIV-1, HIV-2, and SIV. Further, in some aspects, the peptide agent is selected from the group consisting of a tripeptide, an oligopeptide, and a peptidomimetic. Desirably, the method above employs a peptide agent is selected from the group consisting of peptides having the formula Gly-Lys-Gly- $\text{NH}_2$ , Arg-Gln-Gly- $\text{NH}_2$ , Cys-Gln-Gly- $\text{NH}_2$ , Lys-Gln-Gly- $\text{NH}_2$ , Ala-Leu-Gly- $\text{NH}_2$ , Gly-Val-Gly- $\text{NH}_2$ , Val-Gly-Gly- $\text{NH}_2$ , Ala-Ser-Gly- $\text{NH}_2$ , Ser-Leu-Gly- $\text{NH}_2$ , and Ser-Pro-Thr- $\text{NH}_2$ . Additionally, a method of making a pharmaceutical is provided in which the peptide agent  
35 identified by the methods above are incorporated in a pharmaceutical.

Another approach to make a pharmaceutical is also provided, which involves administering to a cell an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>, detecting an inhibition of viral replication in the cell, and incorporating the peptide that causes inhibition of viral replication into the pharmaceutical. This method can involve the use of a peptide

5 that is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>. Further, the method above can involve the step of incorporating an antiviral compound selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors into the pharmaceutical.

10 Additionally, the method above can involve the step of incorporating a carrier into the pharmaceutical.

In another embodiment, a composition for inhibiting viral replication in host cells infected with a virus includes an effective amount of a peptide having the formula  $X_1X_2X_3\text{-R}$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>, wherein R is a modulation group attached to the carboxy-terminus of said peptide and R comprises an amide group or other moiety having similar charge and steric bulk and wherein said composition

15 inhibits viral replication by interrupting viral capsid assembly. This composition can be a peptide selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>. Desirably,  $X_3$  is glycine in these embodiments.

Additionally, the composition above can include a peptide that has the formula  $X_4X_5X_6X_7X_8X_9X_{10}X_1X_2X_3\text{-R}$ , wherein  $X_4$ ,  $X_5$ ,  $X_6$ ,  $X_7$ ,  $X_8$ ,  $X_9$ , and  $X_{10}$  are any amino acid and wherein any one, two, three, four, five, six, or seven amino acids is absent, wherein R is a modulation group attached to the carboxy-terminus of said peptide and R comprises an amide group or other moiety having similar charge and steric bulk.

20

Preferably, the composition above includes a peptide  $X_1X_2X_3$  that is found in the amino acid sequence of the capsid protein of the virus.

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a graph representing the results from an HIV infectivity study conducted in HUT78 cells.

FIGURE 2 is a composite of electron micrographs of untreated HIV particles.

FIGURE 3 is a composite of electron micrographs of HIV particles that have been contacted with the protease inhibitor Ritonavir.

30 FIGURE 4 is a composite of electron micrographs of HIV particles that have been contacted with GPG-NH<sub>2</sub>.

FIGURE 5 illustrates an alignment of the protein sequence corresponding to the carboxyl terminus of the HIV-1 p24 protein (residues 146-231) and protein sequences of HIV-2, SIV, Rous Sarcoma virus (RSV), human T cell leukemia virus-type 1 (HTLV-1), mouse mammary tumor virus (MMTV), Mason-Pfizer monkey virus (MPMV), and Moloney murine leukemia virus (MMLV). The bar represents the major homology region(MHR).



FIGURE 6 is a graph of p24 (pg/ml) detected in the supernatant of HIV infected cells that were cultured in the presence and absence of GPG-NH<sub>2</sub>, Ritonavir (Rito), AZT, or combinations of these agents.

FIGURE 7 illustrates a thin layer chromatography support having separated thereon non-protein bound radioactive labeled compounds from rat urine and rat plasma (rp) sampled after oral feeding of <sup>14</sup>C-GPG-NH<sub>2</sub>, as well as human plasma (Hp) incubated with <sup>14</sup>C-GPG-NH<sub>2</sub>; the sampling times are suffixed and R1-R13 serve to indicate the position of identified radioactive compounds.

FIGURE 8 is a thin layer chromatography support having separated thereon <sup>14</sup>C-GPG-NH<sub>2</sub> that was treated with 0.1N HCl and 50mM KCl and sampled over a 24 hour period; the numbers represent the time of acid exposure and the R serves to indicate the position of the identified <sup>14</sup>C-GPG-NH<sub>2</sub>.

FIGURE 9 is a graph of the partition of <sup>14</sup>C-GPG-NH<sub>2</sub> and its metabolites in rat blood.

FIGURE 10 is a graph of the elimination of radioactivity from the plasma fraction of rats that were orally fed <sup>14</sup>C-GPG-NH<sub>2</sub>.

FIGURE 11 shows crude and fractionated rat plasma proteins that were separated on a 10% SDS/PAGE; 8-f3 refers to the third fraction taken from a sample at 8 hours after administration of <sup>14</sup>C-GPG-NH<sub>2</sub>, 8-f1 refers to the first fraction taken from a sample at 8 hours after administration of <sup>14</sup>C-GPG-NH<sub>2</sub>, 4-f3 refers to the third fraction taken from a sample at 4 hours after administration of <sup>14</sup>C-GPG-NH<sub>2</sub>, 4-f1 refers to the first fraction taken from a sample at 4 hours after administration of <sup>14</sup>C-GPG-NH<sub>2</sub>, 8h, 4h, 2h, and 1h refer to the time the sample was taken after administration of <sup>14</sup>C-GPG-NH<sub>2</sub>, and B1-B4 serve to indicate the position of identified proteins.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The inventor has discovered that modified small peptides having sequences that correspond to viral capsid proteins prevent and/or inhibit viral infection by interrupting proper nucleocapsid formation. Such peptides are useful in the treatment of viral disease, particularly in HIV/AIDS afflicted subjects, and as preventive agents for patients at risk of viral infection, particularly HIV infection, and for use with medical devices where the risk of exposure to virus is significant.

In the disclosure below, the inventor demonstrates that small peptides in amide form that have a sequence that corresponds to viral proteins, such as GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, COG-NH<sub>2</sub>, ROG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> inhibit the replication of viruses, such as HIV-1, HIV-2, and SIV, as measured by viral infectivity assays that monitor the amount of capsid protein or reverse transcriptase activity present in culture supernatant. Further, the inventor presents evidence that these small peptides inhibit viral infectivity by a V3 loop independent mechanism at a stage subsequent to DNA, RNA, and protein synthesis.

Electron microscopic images of HIV particles treated with small peptides reveal that this novel class of antiviral agent interrupts proper capsid assembly in a manner distinct from protease inhibitors. Further, *in vitro* binding assays reveal that the small peptides bind to the major capsid protein (p24) of HIV-1. Because the sequences of several viral capsid proteins are known, such as members of arenavirus, rotavirus, orbivirus, retrovirus, papillomavirus, adenovirus, herpesvirus, paramyxovirus, myxovirus, and hepadnavirus families, several small peptides

that correspond to these sequences can be selected and rapidly screened to identify which ones effectively inhibit and/or prevent viral infection by using the viral infectivity assays or electron microscopy techniques or both described herein, or modifications of these assays as would be apparent to those of skill in the art given the present disclosure.

Several approaches to make biotechnological tools and pharmaceutical compositions comprising small peptides and peptidomimetics (collectively referred to as "peptide agents") that correspond to sequences of viral capsid proteins are given below. Although preferable peptide agents are tripeptides having an amide group at their carboxy termini, such as GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>, the inventor also provides compositions and methods of inhibiting viral replication in host cells, including HIV replication in host cells, comprising a peptide in amide form having the formula X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>-NH<sub>2</sub> or the formula X<sub>4</sub>, X<sub>5</sub>, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>-NH<sub>2</sub>, wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, and X<sub>5</sub> are any amino acid and wherein any one or two amino acids can be absent. Preferred embodiments have a glycine residue as X<sub>3</sub>. In some embodiments, the peptide agents are provided in monomeric form; in others, the peptide agents are provided in multimeric form or in multimerized form. Support-bound peptide agents are also used in several embodiments. Pharmaceutical compositions comprising peptide agents are administered as therapeutics or prophylactics or both for the treatment and/or prevention of viral disease, preferably, HIV infection. In some embodiments, the pharmaceutical compositions comprising peptide agents are administered in combination with other antiviral treatments including nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. The inventor also provides evidence that small peptides are resistant to acid hydrolysis, that a significant amount of small peptide is effectively delivered to blood, plasma, and organ tissue when administered to test subjects, and that the administration of large doses of small peptides to test subjects is relatively nontoxic.

Additionally, the inventor discloses several methods of identifying a peptide agent that inhibits or prevents viral replication or interrupts viral capsid assembly or both. By one approach, an effective amount of a peptide agent is contacted with cells infected with a virus and the cells are analyzed for viral replication or the presence of viral products. Further, by using electron microscopy, the ability of a peptide agent to interrupt capsid assembly can be readily determined. Still further, methods are disclosed that identify a peptide agent that binds to a capsid protein (e.g., p24) and thereby interrupts capsid assembly and, thus, viral replication. Accordingly, a capsid protein (e.g., p24) is contacted with a peptide agent, for example a peptide in amide form having the formula X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, wherein X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are any amino acid, and a complex comprising the capsid protein (e.g., p24) bound with the peptide agent is identified. Reaction mixtures having a viral protein (e.g., p24) and a peptide agent and a biomolecular complex having a viral protein (e.g., p24) joined to a peptide agent are also taught in the present disclosure.

The amide form of small peptides listed in Table 1 below were tested. Many of these small peptides were selected and synthesized because they either fully or partially correspond to sequences in HIV and/or SIV viral proteins. The small peptides of Table 1 were synthesized according to the method disclosed in Example 1 below, but could of course be synthesized by any method known in the art.

glutaminy-glycine amide (RQG-NH<sub>2</sub>), lysyl-glutaminy-glycine amide (KQG-NH<sub>2</sub>), alanyl-leucyl-glycine amide (ALG-NH<sub>2</sub>), glycyl-valyl-glycine amide (GVG-NH<sub>2</sub>), valyl-glycyl-glycine amide (VGG-NH<sub>2</sub>), alanyl-seryl-glycine amide (ASG-NH<sub>2</sub>), seryl-leucyl-glycine amide (SLG-NH<sub>2</sub>), and seryl-prolyl-threonine amide (SPT-NH<sub>2</sub>). In addition to those synthesized, many tripeptides were also purchased from Bachem AG, Switzerland, including but not limited to, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, and GPG-NH<sub>2</sub>.

In the toxicology experiments and experiments that evaluated the effects of small peptide treatment in combination with conventional antiviral therapies, the peptides were obtained as follows. For the initial experiments, solid phase peptide synthesis was performed using an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, CA). Each synthesis used a p-methylbenzylhydramine solid phase support resin (Peptide International, Louisville, KY) yielding a carboxyl terminal amide when the peptides are cleaved off from the solid support by acid hydrolysis. All amino acids for use in synthesis contained t-butylcarbonyl groups protecting the  $\alpha$ -NH<sub>2</sub> group and were obtained from Novabiochem AG, Switzerland. The protecting groups were removed from the synthesized peptides that were cleaved from the solid support resin by treatment with trifluoromethane sulfonic acid, giving peptides with an amino (-NH<sub>2</sub>) modulation group instead of a hydroxyl (-OH) group at the carboxyl terminus. Prior to use, the peptides were purified by reverse phase high performance liquid chromatography and sequenced on an Applied Biosystems 473A peptide sequencer. In addition, the tripeptide GPG having either an amide (CO-NH<sub>2</sub>; GPG-NH<sub>2</sub>) or carboxyl (COOH; GPG-OH) terminus was purchased from Bachem AG, Switzerland.

In the disclosure below, several assays that were used to identify small peptides that inhibit HIV-1, HIV-2, and SIV infection are described.

#### *HIV and SIV infectivity assays*

The peptides made according to Example 1 were used in several HIV-1, HIV-2, and SIV infection assays. The efficiency of HIV-1, HIV-2, and SIV infection was monitored by reverse transcriptase activity, the concentration of p24 protein in the cell supernatant, and by microscopic evaluation of HIV-1 syncytia formation.

In initial experiments, several tripeptides were screened for the ability to inhibit HIV-1, HIV-2, and SIV infection in H9 cells. Once inhibitory tripeptides were identified, more specific assays were conducted to determine the effect of varying concentrations of the selected tripeptides and combination treatments (e.g., the use of more than one tripeptide in combination).

In the example below, an approach that was used to screen several tripeptides for their ability to inhibit HIV-1, HIV-2, and SIV infection is disclosed.

#### **EXAMPLE 2**

In this example, the methods that were used to analyze the ability of various tripeptides to inhibit HIV-1, HIV-2, and SIV replication are disclosed. In Experiments 1 and 2, approximately 200,000 H9 cells were infected with HIV-1, HIV-2 or SIV at 25 TCID<sub>50</sub> to test the inhibitory effect of the following synthesized tripeptides LKA-NH<sub>2</sub>, ILK-NH<sub>2</sub>, GPQ-NH<sub>2</sub>, GHK-NH<sub>2</sub>, GKG-NH<sub>2</sub>, ACQ-NH<sub>2</sub>, CQG-NH<sub>2</sub>, ARV-NH<sub>2</sub>, KAR-NH<sub>2</sub>, HKA-NH<sub>2</sub>, GAT-NH<sub>2</sub>, KAL-NH<sub>2</sub>, and GPG-NH<sub>2</sub>. Accordingly, the H9 cells were resuspended with or without the different peptides (approximately 100 $\mu$ M) in 1ml of

RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100u/ml), and streptomycin (100u/ml), all available through GIBCO, and Polybrene ( g/ml), available through Sigma. Thereafter, viruses were added at 25 TCID<sub>50</sub> in a volume of 20-30µl. Cells were incubated with virus at 37°C for 1hr then pelleted at 170xg for 7 minutes. The cells were then washed three times in RPMI medium without peptides at room temperature and pelleted at 170xg for 7 minutes, as above. After the final wash, the cells were resuspended in RPMI culture medium containing the peptides in a 24-well plate (Costar corporation) and were kept at 37°C in 5% CO<sub>2</sub> with humidity.

Culture supernatants were collected and analyzed when the medium was changed at 4, 7, 10, and 14 days post infection. To monitor the replication of virus, reverse transcriptase (RT) activity in the supernatants was assayed using a commercially available Lenti-RT activity kit. (Cavidi Tech, Uppsala, Sweden). The amount of RT was determined with the aid of a regression line of standards. The results are presented as absorbance values (OD) and higher absorbance indicates a higher protein concentration and greater viral infection. Syncytium formation was also monitored by microscopic examination. Tables 2 and 3 show the absorbance values of the cell culture supernatants of Experiments 1 and 2 respectively.

In Experiment 3, (Table 4), approximately 200,000 H9 cells were infected with HIV-1, HIV-2 or SIV at 25 TCID<sub>50</sub> to test the inhibitory effect of different concentrations of peptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub> and CQG-NH<sub>2</sub> and combinations of these peptides (the indicated concentration corresponds to the concentration of each tripeptide). As above, H9 cells were resuspended with or without the different peptides at varying concentrations in 1ml of RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100u/ml), and streptomycin (100u/ml), and Polybrene ( g/ml). Thereafter, viruses were added at 25 TCID<sub>50</sub> in a volume of 20-30µl. Cells were incubated with the indicated virus at 37°C for 1hr then pelleted at 170xg for 7 minutes. The cells were then washed three times in RPMI medium without peptides at room temperature and pelleted at 170xg for 7 minutes, as above. After the final wash, the cells were resuspended in RPMI culture medium containing the peptides in a 24-well plate (Costar corporation) and kept at 37°C in 5% CO<sub>2</sub> with humidity.

Culture supernatants were collected when the medium was changed at 4, 7, and 11 days post infection. As above, the replication of each virus was monitored by detecting reverse transcriptase (RT) activity in the supernatants using the Lenti-RT activity kit. (Cavidi Tech). The amount of RT was determined with the aid of a regression line of standards. The results are presented as absorbance values (OD) and higher absorbance indicates a higher protein concentration and greater viral infection. Table 4 shows the absorbance values of the cell culture supernatants of Experiment 3.

In Experiment 4, (Table 5) approximately 200,000 H9 cells were infected with HIV-1 at 25 TCID<sub>50</sub> to test the inhibitory effect of different concentrations of peptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub> and CQG-NH<sub>2</sub> and combinations of these peptides (the indicated concentration corresponds to the total concentration of tripeptide). As above, H9 cells were resuspended with or without the different peptides at varying concentrations in 1ml of RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100u/ml), and streptomycin

(100u/ml), and Polybrene ( g/ml). Thereafter, viruses were added at 25 TCID<sub>50</sub> in a volume of 20-30μl. Cells were incubated with the indicated virus at 37°C for 1hr then pelleted at 170xg for 7 minutes. The cells were then washed three times in RPMI medium without peptides at room temperature and pelleted at 170xg for 7 minutes, as above. After the final wash, the cells were resuspended in RPMI culture medium containing the peptides in a 24-well plate

5 (Costar corporation) and kept at 37°C in 5% CO<sub>2</sub> with humidity.

Culture supernatants were collected when the medium was changed at 4, 7, and 11 days post infection. As above, the replication of each virus was monitored by detecting reverse transcriptase (RT) activity in the supernatants using the Lenti-RT activity kit. (Cavidi Tech). The amount of RT was determined with the aid of a regression line of standards. The results are presented as absorbance values (OD) and higher absorbance indicates a higher protein

10 concentration and greater viral infection. Table 5 shows the absorbance values of the cell culture supernatants of Experiment 4. The supernatant analyzed at day 11 was diluted 5-fold so that detection could be more accurately determined.

In Experiment 5, (Table 6) approximately 200,000 H9 cells were infected with HIV-1 at 25 TCID<sub>50</sub> to test the inhibitory effect of different concentrations of peptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub> and CQG-NH<sub>2</sub> and combinations of these peptides. As above, H9 cells were resuspended with or without the different peptides at varying concentrations

15 in 1ml of RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), penicillin (100u/ml), streptomycin (100u/ml), and Polybrene ( g/ml). Thereafter, viruses were added at 25 TCID<sub>50</sub> in a volume of 20-30μl. Cells were incubated with the indicated virus at 37°C for 1hr then pelleted at 170xg for 7 minutes. The cells were then washed three times in RPMI medium without peptides at room temperature and pelleted at 170xg for

20 7 minutes, as above. After the final wash, the cells were resuspended in RPMI culture medium containing the peptides in a 24-well plate (Costar corporation) and kept at 37°C in 5% CO<sub>2</sub> with humidity.

Culture supernatants were collected when the medium was changed at 4, 7, and 14 days post infection. The replication of each virus was monitored by detecting the presence of p24 in the supernatants. HIV p24 antigen was determined using a commercially available HIV p24 antigen detection kit (Abbott). The results are presented as

25 absorbance values (OD) and higher absorbance indicates a higher protein concentration and greater viral infection. In some cases, serial dilutions of the supernatants were made so as to more accurately detect p24 concentration. Table 6 shows the absorbance values of the cell culture supernatants of Experiment 5. As discussed in greater detail below, it was discovered that the tripeptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub> and CQG-NH<sub>2</sub> and combinations of these peptides effectively inhibit HIV-1, HIV-2, and SIV infection.

In experiment 6 (Table 7 and Figure 1), approximately 200,000 HUT78 cells were infected with HIV-1 at 25 TCID<sub>50</sub> to test the inhibitory effect of GPG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>. The HUT cells were resuspended in 1ml of RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, GIBCO), penicillin (100u/ml), streptomycin (100u/ml) and Polybrene (Sigma, 2μg/ml) with or without the presence of the different small peptides (100μM) mentioned above. Thereafter, the HIV-

30 1 virus was added at 25 TCID<sub>50</sub> in a volume of 20μl. Cells were incubated with the virus at 37°C for one hour and,

35

subsequently, the cells were pelleted at 170xg for seven minutes. The cells were then washed three times in RPMI medium without peptides at room temperature by cell sedimentation at 170xg for seven minutes, as above. After the final wash, the cells were resuspended in RPMI culture medium containing the peptides in 24-well plate (Costar corporation) and were kept at 37°C in 5% CO<sub>2</sub> with humidity. Culture supernatants were collected when medium was changed at day 4, 7, and 11 post infection and viral p24 production was monitored by using an HIV-1 p24 ELISA kit (Abbott Laboratories, North Chicago, USA). As discussed below, it was discovered that the small peptides RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> effectively inhibit HIV-1 infection.

TABLE 2

Experiment 1 - (peptides made on site)

Day 7 RT

Day 10 RT

Tripeptide (100 M)	HIV-1	HIV-2	SIV	HIV-1	HIV-2	SIV	HIV-1 Syncytia
LKA-NH <sub>2</sub>	0.568*	3.649	3.577	2.429	2.769	2.452	pos
ILK-NH <sub>2</sub>	0.365	3.467	3.180	2.033	2.791	2.255	pos
GPD-NH <sub>2</sub>	0.204	3.692	1.542	1.965	2.734	2.176	pos
GHK-NH <sub>2</sub>	0.289	3.522	0.097	2.151	2.931	2.384	pos
GKG-NH <sub>2</sub>	0.080	0.160	0.421	0.074	0.147	0.099	neg
ACQ-NH <sub>2</sub>	0.117	3.418	1.241	0.904	2.753	2.746	pos
COG-NH <sub>2</sub>	0.091	0.217	0.747	0.108	0.296	0.110	neg
ARV-NH <sub>2</sub>	0.156	3.380	0.210	1.528	3.003	1.172	pos
KAR-NH <sub>2</sub>	0.380	3.419	0.266	2.779	2.640	1.722	pos
HKA-NH <sub>2</sub>	0.312	3.408	0.416	2.546	2.669	2.520	pos
GAT-NH <sub>2</sub>	0.116	3.461	0.892	1.565	2.835	2.343	pos
KAL-NH <sub>2</sub>	0.246	3.372	1.091	1.995	2.749	2.524	pos
GPG-NH <sub>2</sub>	0.068	0.735	0.138	0.074	0.145	0.103	neg
NO PEPTIDE CONTROL	0.251	1.675	1.227	2.217	2.657	3.030	pos

\*Values represent optical density (OD)

TABLE 3

*Experiment 2 - (peptides made on site)*

Day 7 RT

Day 10 RT

Tripeptide (100 M)	HIV-1	HIV-2	SIV	HIV-1	HIV-2	SIV	HIV-1 Syncytia
LKA-NH <sub>2</sub>	0.894*	1.689	0.724	2.989	2.637	2.797	pos
ILK-NH <sub>2</sub>	0.581	1.692	0.515	2.950	2.557	2.632	pos
GPQ-NH <sub>2</sub>	0.884	1.511	0.574	2.848	2.382	2.319	pos
GHK-NH <sub>2</sub>	0.829	1.936	0.396	3.013	2.418	2.394	pos
GKG-NH <sub>2</sub>	0.145	0.283	0.116	0.345	1.637	0.204	neg
ACQ-NH <sub>2</sub>	0.606	1.661	0.612	2.831	2.505	2.606	pos
CQG-NH <sub>2</sub>	0.143	1.241	0.120	1.546	2.501	1.761	neg
ARV-NH <sub>2</sub>	0.618	2.237	0.212	2.829	2.628	3.004	pos
KAR-NH <sub>2</sub>	0.753	1.904	1.034	2.928	2.742	2.672	pos
HKA-NH <sub>2</sub>	1.081	1.678	0.455	2.794	2.560	2.623	pos
GAT-NH <sub>2</sub>	0.776	1.707	0.572	2.800	2.565	2.776	pos
KAL-NH <sub>2</sub>	0.999	1.757	0.511	2.791	2.383	2.663	pos
GPG-NH <sub>2</sub>	0.090	0.093	0.067	0.143	0.575	0.139	neg
NO PEPTIDE CONTROL	0.809	1.774	0.578	2.711	2.528	2.911	pos

*\*Values represent optical density (OD)*

TABLE 4

*Experiment 3 - (peptides obtained from Bachem)*

Day 7 RT

Day 10 RT

Tripeptide	HIV-1	HIV-2	SIV	HIV-1	HIV-2	SIV
NO PEPTIDE CONTROL	1.558*	1.718	1.527	2.521	2.716	2.091
GPG-NH <sub>2</sub> 5μM	1.527	1.735	0.753	2.398	2.329	2.201
GPG-NH <sub>2</sub> 20μM	0.239	0.252	0.197	0.692	1.305	0.779
GKG-NH <sub>2</sub> 5μM	1.587	1.769	0.271	1.683	2.510	1.709
GKG-NH <sub>2</sub> 20μM	1.616	1.759	1.531	2.036	2.646	2.482
GKG-NH <sub>2</sub> 100μM	0.823	0.828	1.005	1.520	1.947	1.382
COG-NH <sub>2</sub> 5μM	1.547	1.760	1.159	2.028	2.466	2.821
COG-NH <sub>2</sub> 20μM	1.578	1.748	0.615	1.484	2.721	2.158
COG-NH <sub>2</sub> 100μM	1.520	1.715	0.795	2.014	2.815	2.286
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> 5μM	1.430	1.738	1.131	1.998	2.770	2.131
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> 20μM	0.129	0.244	0.123	0.164	1.110	0.309
GPG-NH <sub>2</sub> + COG-NH <sub>2</sub> 5μM	1.605	1.749	1.737	1.866	2.814	2.206
GPG-NH <sub>2</sub> + COG-NH <sub>2</sub> 20μM	0.212	0.194	0.523	0.397	1.172	0.910
GKG-NH <sub>2</sub> + COG-NH <sub>2</sub> 5μM	1.684	1.717	1.725	1.848	2.778	2.949
GKG-NH <sub>2</sub> + COG-NH <sub>2</sub> 20μM	1.490	1.792	1.670	1.891	2.799	2.889
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> 5μM	1.652	1.743	1.628	1.999	2.777	2.659
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> 20μM	0.165	0.119	0.317	0.307	0.447	0.389

*\*Values represent optical density (OD)*



TABLE 5

*Experiment 4 - (peptides obtained from Bachem)*

	Day 7 RT	Day 10 RT
Tripeptide	HIV-1	HIV-1 (1:5)
NO PEPTIDE CONTROL	3.288*	1.681
GPG 5 $\mu$ M	2.970	1.107
GPG 15 $\mu$ M	0.894	0.095
GPG 45 $\mu$ M	0.177	0.034
GPG 100 $\mu$ M	0.150	0.033
GKG 5 $\mu$ M	3.303	1.287
GKG 15 $\mu$ M	3.551	1.530
GKG 45 $\mu$ M	3.126	0.410
COG 5 $\mu$ M	2.991	1.459
COG 15 $\mu$ M	2.726	1.413
COG 45 $\mu$ M	3.124	1.364
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> 5 $\mu$ M	2.266	0.438
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> 15 $\mu$ M	0.216	0.044
GPG-NH <sub>2</sub> + COG-NH <sub>2</sub> 5 $\mu$ M	2.793	0.752
GPG-NH <sub>2</sub> + COG-NH <sub>2</sub> 15 $\mu$ M	0.934	0.110
GKG-NH <sub>2</sub> + COG-NH <sub>2</sub> 5 $\mu$ M	3.534	1.305
GKG-NH <sub>2</sub> + COG-NH <sub>2</sub> 15 $\mu$ M	3.355	2.013
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> + COG-NH <sub>2</sub> 5 $\mu$ M	2.005	0.545
GPG-NH <sub>2</sub> + GKG-NH <sub>2</sub> + COG-NH <sub>2</sub> 15 $\mu$ M	0.851	0.110

*\*Values represent optical density (OD)*

TABLE 6

*Experiment 5 - (peptides made on site)*

Tripeptide ( $\mu\text{M}$ )		p24 (OD)	p24 (pg/ml)	reduction (%)
Day 7	HIV-1			
NO PEPTIDE CONTROL		$1.093 \times 10^2$	$3.94 \times 10^4$	0
GPG-NH <sub>2</sub> (20)		1.159	$4.21 \times 10^2$	99
GPG-NH <sub>2</sub> (100)		0.508	$1.60 \times 10^2$	100
GPG-NH <sub>2</sub> (300)		0.557	$1.80 \times 10^2$	100
GKG-NH <sub>2</sub> (100)		$0.566 \times 10^1$	$1.83 \times 10^3$	95
GKG-NH <sub>2</sub> (300)		1.08	$3.88 \times 10^2$	99
GKG-NH <sub>2</sub> (1000)		0.79	$2.73 \times 10^2$	100
CQG-NH <sub>2</sub> (100)		$1.51 \times 10^1$	$5.62 \times 10^3$	86
CQG-NH <sub>2</sub> (300)		$0.59 \times 10^1$	$1.92 \times 10^3$	95
CQG-NH <sub>2</sub> (1000)		0.91	$3.20 \times 10^2$	99
combined*		0.65	$2.17 \times 10^2$	100
Day 14	HIV-1			
NO PEPTIDE CONTROL		$0.46 \times 10^4$	$1.41 \times 10^6$	0
GPG-NH <sub>2</sub> (20)		$1.12 \times 10^2$	$4.06 \times 10^4$	97
GPG-NH <sub>2</sub> (100)		1.76	$6.63 \times 10^2$	100
GPG-NH <sub>2</sub> (300)		1.35	$4.98 \times 10^2$	100
GKG-NH <sub>2</sub> (100)		$1.48 \times 10^3$	$5.51 \times 10^5$	61
GKG-NH <sub>2</sub> (300)		$0.33 \times 10^1$	$8.70 \times 10^2$	100
GKG-NH <sub>2</sub> (1000)		$0.11 \times 10^1$	$2.40 \times 10^2$	100
CQG-NH <sub>2</sub> (100)		$0.48 \times 10^4$	$1.47 \times 10^6$	0
CQG-NH <sub>2</sub> (300)		$0.11 \times 10^2$	$2.40 \times 10^3$	100
CQG-NH <sub>2</sub> (1000)		$0.13 \times 10^1$	$2.80 \times 10^2$	100
combined*		1.01	$3.61 \times 10^2$	100

\*100 $\mu\text{M}$  GPG · NH<sub>2</sub> + GKG · NH<sub>2</sub> + CQG · NH<sub>2</sub>

\*Values represent optical density (OD)

TABLE 7

*Experiment 6 - (peptides made on site)*

Tripeptide (100 $\mu$ M)		p24 (pg/ml)	reduction (%)
Day 7	HIV-1		
NO PEPTIDE CONTROL		$2.0 \times 10^4$	0
GPG-NH <sub>2</sub>		$5.6 \times 10^2$	97
RQG-NH <sub>2</sub>		$1.13 \times 10^2$	99
KQG-NH <sub>2</sub>		$1.54 \times 10^2$	99
ALG-NH <sub>2</sub>		$0.42 \times 10^2$	100
GVG-NH <sub>2</sub>		$1.5 \times 10^4$	25
VGG-NH <sub>2</sub>		$1.0 \times 10^4$	50
ASG-NH <sub>2</sub>		$1.5 \times 10^4$	25
SLG-NH <sub>2</sub>		$1.14 \times 10^2$	99
SPT-NH <sub>2</sub>		$1.5 \times 10^4$	25

5 *Small peptides inhibit and/or prevent HIV-1, HIV-2, and SIV infection*

Of the small peptides listed in Table 1, GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> inhibited and/or prevented HIV-1 infection and GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, and GPG-NH<sub>2</sub> were also shown to inhibit or prevent HIV-2 and SIV infection. It should be understood that the small peptides RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> were not analyzed for their ability to prevent or inhibit HIV-2 or SIV infection but, given the fact that HIV-2 and SIV share significant homology in capsid protein structure at the region to which the small peptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> correspond, an inhibition or prevention of HIV-2 or SIV infection or both is expected.

The results for Experiments 1-6 (shown in Tables 2-7 and Figure 1), demonstrate that small peptides in amide form that correspond to viral capsid protein sequence having a glycine as the carboxyterminal amino acid, GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, and SLG-NH<sub>2</sub>, inhibited or prevented HIV infection. Peptides containing a carboxyterminal alanine residue, Leu-Lys-Ala (LKA) and His-Lys-Ala (HKA) or a carboxyterminal glutamine residue, Gly-Pro-Gln (GPQ) and Ala-Cys-Gln (ACQ) did not prevent HIV infection. Glycine at the amino terminus was not an inhibitory factor, however, because the peptides with an amino terminal glycine residue, Gly-Pro-Gln (GPQ), Gly-His-Lys (GHK), and Gly-Ala-Thr (GAT) failed to prevent infection and HIV-1 syncytia formation. Further, peptides with other uncharged polar side chains such as Gly-Pro-Gln (GPQ), Ala-Cys-Gln (ACQ), and Gly-Ala-Thr (GAT) or non-polar side chains at the carboxy terminus such as Ala-Arg-Val (ARV), His-Lys-Ala (HKA), and Lys-Ala-Leu (KAL), and Leu-Lys-Ala (LKA) failed to prevent infection. Although a glycine residue at the carboxy terminus appears to be associated with the inhibition of HIV and SIV infection, other amino acid residues or

modified amino acid residues at the carboxy terminus of a small peptide can also inhibit HIV and SIV infection. For example, it was shown that Ser-Pro-Thr (SPT) inhibited or prevented HIV-1 infection.

In some experiments it appeared that the effect of the small peptides on HIV-1, HIV-2, and SIV infection was concentration and time dependent. Concentrations of GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, and GPG-NH<sub>2</sub> and combinations thereof, as low as 5μM and 20μM were shown to be effective at reducing HIV-1, HIV-2, and SIV infection. At 100μM or greater, however, the tripeptides GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, and GPG-NH<sub>2</sub> and combinations thereof more efficiently inhibited HIV-1, HIV-2, and SIV infection. As shown in Table 6, 300μM of GKG-NH<sub>2</sub> and CQG-NH<sub>2</sub> reduced HIV-1 infectivity by almost 100%, as detected by the presence of p24 antigen in cell supernatants. The percent reduction tabulated in Table 6 was calculated by dividing amount of p24 antigen detected in the peptide-treated sample by the amount of p24 antigen detected in the control sample, multiplying this dividend by 100 to obtain a percentage, and subtracting the dividend percentage by 100%. For example, the percent reduction exhibited by GPG-NH<sub>2</sub> is:

$$\frac{5.6 \times 10^2}{2.0 \times 10^4} \times 100 = 3\% \quad \text{and} \quad 100\% - 3\% = 97\%.$$

15

In the first five experiments (Tables 2-6) it was shown that the tripeptides GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, and GPG-NH<sub>2</sub> and combinations thereof, inhibit HIV-1, HIV-2, and SIV infection at concentrations equal to or greater than 5μM.

In the sixth experiment (Table 7 and Figure 1), it was shown that the small peptides RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> effectively inhibit and/or prevent HIV-1 infection at 100μM. As shown in Table 7, a nearly 100% reduction of virus, as measured by the amount of capsid protein p24 in the supernatant, was achieved with the small peptides RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, and SLG-NH<sub>2</sub>. The percent reduction of p24 shown in Table 7 was calculated as described for Table 6, above. Although GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> were less effective at inhibiting or preventing HIV-1 infection at 100μM, it is believed that the tripeptides are more effective at higher concentrations. The data presented in experiments 1-6, shown in Tables 2-7 and Figure 1, demonstrate that small peptides that correspond to sequences of a viral capsid protein are effective antiviral agents over a wide-range of concentrations.

25

In order to better understand small peptide-mediated viral inhibition, several studies on DNA synthesis, RNA synthesis, and protein expression were conducted. These experiments are discussed below.

*Small peptides inhibit viral infectivity at a stage subsequent to DNA synthesis, RNA synthesis, and protein expression*

30

To study proviral DNA and viral RNA synthesis, DNA and RNA from HIV-1 infected H-9 cells cultured in the presence of a small peptide were prepared at various time points (0-48 h). Southern blot analysis revealed that HIV-1 DNA was synthesized in the presence of GPG-NH<sub>2</sub> and the amount of proviral DNA was almost equal at various concentrations (0-2,000 μM) of the small peptide during the first 24 h. These results prove that small peptides, such

as GPG-NH<sub>2</sub>, have no inhibitory effect on HIV-1 entry and DNA synthesis, and coincide with the finding that the small peptides do not inhibit HIV-1 reverse transcriptase activity.

By Northern blot analysis, three RNA bands (9.2, 4.3, 2.0 kb) were detected 24-48 h after infection. The 9.2 kb RNA acts as both the genomic RNA and as the mRNA for the *gag* and *pol* genes. The 4.3 kb singly-spliced RNA represents at least the *env* gene, and the multiply-spliced 2 kb RNA encodes for the regulatory genes. GPG-NH<sub>2</sub> at 20 μM had no inhibitory effect on expression of these RNAs up to 48 h post infection. At 200 μM and 2,000 μM a reduction of HIV-1 RNA was noticed 48 h after infection that probably reflects inhibition of the second replication cycle. These results established that small peptides do not inhibit HIV-1 replication at the transcription step, nor do they affect the splicing of transcripts.

In the experiments designed to determine whether HIV-1 properly expresses protein in the presence of small peptides, no significant effect on protein expression or modification was observed. In one experiment, however, an aberrant migration of gp160/gp120 on a polyacrylamide gel was seen. In the presence GPG-NH<sub>2</sub> (20 μM or more), gp160 and/or gp120 was observed to electrophorese to a position on a polyacrylamide gel representative of a molecular weight of slightly less than 120,000 Da. This result was not reproducible and a change in migration of the *gag*-proteins p17 or p24 was not observed. Studies to analyze glycosylation of the virus protein in the presence of GPG-NH<sub>2</sub> showed that there was no effect on either N- or O-linked glycosylation. Also, glycosylation on recombinantly (in vaccinia virus) produced gp160 was not affected by GPG-NH<sub>2</sub>. Furthermore, GPG-NH<sub>2</sub> was found not to affect the activity of the HIV-1 specific protease.

In the experiments presented above, it was demonstrated that small peptides interfere with HIV infectivity at a late stage of the HIV replicative cycle. GPG-NH<sub>2</sub> was unable to disrupt DNA synthesis, RNA synthesis, protein synthesis, and protein glycosylation. In the following disclosure, more evidence that small peptides, such as GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>, inhibit viral infection at a late stage in the replicative cycle is disclosed and, in a broader sense, another technique that can be used to screen other small peptides and derivatives thereof for the ability to inhibit viral infection, such as HIV or SIV infection, is provided. Accordingly, discussed below are several electron microscopy experiments in which HIV-1 infected cells were incubated in the presence and absence of a small peptide.

#### *Small peptides interfere with assembly of the nucleocapsid*

Once it had been discovered that the small peptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> inhibited HIV infection, electron microscopy was used to further analyze HIV infected cells that had been incubated with a small peptide. (See Figures 2, 3, and 4). As shown in Figure 4, electron microscopic analysis revealed that contact with GPG-NH<sub>2</sub> interrupted proper viral nucleocapsid formation.

In this set of experiments, HUT78 cells were infected with HIV-1 SF-2 virus at 300TCID<sub>50</sub> for 1hr at 37°C. Subsequently, the infected cells were washed and pelleted 3 times, as described in Example 2. Thereafter, the cells were resuspended in RPMI culture medium supplemented with 10% FBS, antibiotics (100u/ml) and polybrene

(3.2µg/ml). GPG-NH<sub>2</sub> was then added into the cell cultures 3, 5 or 7 days post infection at concentration of 1µM or 10µM. A control sample was administered 0.5µM Ritonavir (a protease inhibitor).

The cells were cultured until day 14, at which point, the cells were fixed in 2.5% glutaraldehyde by conventional means. The fixed cells were then postfixed in 1% OsO<sub>4</sub> and were dehydrated, embedded with epoxy resins, and the blocks were allowed to polymerize. Epon sections of virus infected cells were made approximately 60-80nm thin in order to accommodate the width of the nucleocapsid. The sections were mounted to grids stained with 1.0% uranyl acetate and were analyzed in a Zeiss CEM 902 microscope at an accelerating voltage of 80 kV. The microscope was equipped with a spectrometer to improve image quality and a liquid nitrogen cooling trap was used to reduce beam damage. The grids having sections of control and GPG-NH<sub>2</sub> incubated cells were examined in several blind studies.

Electron microscopy of untreated HIV particles revealed the characteristic conical-shaped nucleocapsid and enclosed uniformly stained RNA that stretched the length of the nucleocapsid. (See Figure 2). In contrast, Figure 3 presents two electron micrographs showing several HIV-1 particles that were produced in the presence of the viral protease inhibitor Ritonavir. Infected cells that had been treated with Ritonavir exhibited malformed structures that did not have a discernable nucleocapsid, as was expected. (See Figure 3). Figure 4 presents electron micrographs showing viral particles that had been produced in the presence of GPG-NH<sub>2</sub>. Cells having HIV-1 particles that were treated with GPG-NH<sub>2</sub> exhibited HIV-1 particles with discernable capsid structures that are distinct from the Ritonavir-treated particles. More specifically, in some tripeptide-treated viral particles, the conical-shaped capsid structure appeared to be relatively intact but the RNA was amassed in a ball-like configuration either outside the capsid or at the top (wide-end) of the capsid. Still further, some capsids were observed to have misshapen structures with little or no morphology resembling a normal nucleocapsid and RNA was seen to be either outside the structure or inside the structure at one end. From these studies it was clear that small peptides interfered with proper formation of the nucleocapsid and that this inhibition of capsid development occurred at a step distinct from the action of the protease inhibitor Ritonavir.

More evidence that tripeptides in amide form, such as GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>, interfere with capsid assembly was revealed when a binding assay with p24 as a target biomolecule was performed. The details of the p24 binding assay are provided below.

*Small peptides bind to the major capsid protein (p24)*

Experiments were performed to directly study whether small peptides have the ability to interact with the mature capsid protein (CA) or p24 and thereby interfere with nucleocapsid formation. In this set of experiments, a p24 binding assay was performed that assessed the ability of radiolabeled GPG-NH<sub>2</sub> to bind to p24.

A dialysis-based binding assay was conducted using a dialysis membrane with a pore size of less than 10kD. (Slide-A-Lyzer, Pierce). Fifty microliters of a 10µM stock of the recombinant proteins p24 and gp120 (gifts from the AIDS program, NCIB) and BSA (Sigma) were introduced into separate dialysis membranes and the proteins were

dialyzed at 4°C for 2 days against a 500ml solution composed of 150mM NaCl and 50mM Tris-HCl, pH 7.4 buffer and 27.5 M of  $^{14}\text{C}$ -GPG-NH<sub>2</sub> (Amersham Ltd. UK). Subsequently, ten or five microliter aliquots of the dialyzed p24, gp120, and BSA were removed and mixed with 3ml of ReadySafe (Beckman) in a scintillation vial. The  $\text{C}^{14}$  was then detected by scintillation counting.

5 In Table 8, the results from a representative dialysis experiment are provided. Notably, an association of p24 with GPG-NH<sub>2</sub> was observed upon dialysis equilibration. The amount of radioactive GPG-NH<sub>2</sub> associated with p24 was 7.5 times greater than that present in the buffer. In contrast, no appreciable amount of radioactive GPG-NH<sub>2</sub>, over the amount present in the dialysis buffer, was associated with either gp120 or BSA. These results prove that small peptides, such as GPG-NH<sub>2</sub>, bind to p24 and through this interaction interrupt proper nucleocapsid formation.

10

TABLE 8

Sample:	dialysis buffer	p24	gp120	BSA
$\mu\text{Ci/ml}$	1.816	13.712	1.745	1.674
times buffer	1.000	7.551	0.961	0.922

In the following disclosure, additional evidence that small peptides, such as GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>, inhibit HIV and SIV infection by a mechanism that is different from the way that AZT or Ritonavir inhibit these viruses is provided.

15

*Small peptides inhibit HIV-1 strains that are resistant to AZT or Ritonavir*

The ability of small peptides to inhibit HIV-1 strains that are resistant to either the nucleoside analogue AZT or the protease inhibitor Ritonavir. The HIV-1 resistant isolates were cultivated in peripheral blood mononuclear cells (PBMC) and the supernatants were collected as virus stocks. Titration of TCID<sub>50</sub> (50% tissue culture infectious dose) were performed on PBMC and the titers were calculated according to the Reed and Muench formula. 400,000 PBMC were infected with 25 TCID<sub>50</sub> of those viruses (HIV-1 SF162 was used as a control) by adsorption in 37°C for one hour then washed three times. The cells were resuspended in culture medium containing either no drug, GPG-NH<sub>2</sub> (100  $\mu\text{M}$ ), AZT (5 $\mu\text{M}$ ), or Ritonavir (0.1 $\mu\text{M}$ ) and incubated in 37°C, CO<sub>2</sub> and humidity. Culture medium was changed every four days and the HIV-1 p24 antigen protein in the supernatants was monitored by ELISA (Table 9).

20

As shown in Table 9, GPG-NH<sub>2</sub> had a potent anti-viral effect on either AZT or Ritonavir resistant HIV strains. The results in this experiment substantiate the data presented above and prove that small peptides inhibit HIV replication at a different stage than AZT and Ritonavir. Additionally, the treatment of "street strains" of HIV was accomplished with GPG-NH<sub>2</sub>, as disclosed in U.S. Patent No. 5,627,035 to Vahlne et al., herein incorporated by reference in its entirety. Given that they are also derived from the sequence of the HIV viral protein, the peptides GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub> are also useful in the treatment of AZT and Ritonavir resistant HIV infections, as well as street strains of HIV.

25

30

TABLE 9

Types	Number	Control (%)	GPG 100 $\mu$ M (% reduction)	AZT 5 $\mu$ M (% reduction)	Rito <sup>b</sup> 0.1 $\mu$ M (% reduction)
low AZT	p7261	130000* (0)	< 500 (100%)	< 500 (100%)	nt
inter AZT	p7163	107000 (0)	< 500 (100%)	22200 (79%)	nt
high AZT	p7227	114000 (0)	< 500 (100%)	68000 (40%)	nt
low PI	p7300	146000 (0)	< 500 (100%)	nt <sup>a</sup>	64000 (56%)
high PI	p7141	114000 (0)	< 500 (100%)	nt	98000 (14%)

\*HIV-1 p24 values are shown in pg/ml and are averages of duplicate experiments taken 14 days post infection.

5

<sup>a</sup>not tested

<sup>b</sup>Ritonavir

Low AZT: isolated with a low resistance to AZT.

Inter AZT: isolated with a intermediate resistance to AZT.

10

High AZT: isolated with a high resistance to AZT.

Low PI: isolated with a low resistance to protease inhibitor.

High PI: isolated with a high resistance to protease inhibitor.

15

In further support of the data presented above, several HIV-1 infectivity experiments on an HIV-1 mutant that lacked the GPG-motif in its V3 loop were performed. These experiments, detailed below, established that GPG-NH<sub>2</sub>-mediated HIV-1 inhibition occurs in a V3 loop independent fashion. The V3 loop of HIV-1 *env* glycoprotein gp120 contains a conserved GPG sequence at the tip of the loop that may be involved in virus replication. To determine whether GPG-NH<sub>2</sub> inhibited HIV-1 infection by perturbing a V3 loop interaction, a V3 loop HIV-1 mutant provirus was constructed. This mutant provirus lacking the GPG domain was tested for its ability to infect cells in infectivity assays and was analyzed by immunocytochemistry and electron microscopy. The example below describes the construction of the mutant provirus, the assay for HIV-1 infectivity, the determination of the structure of the mutant viral particles by immunocytochemistry and electron microscopy, and the discovery that GPG-NH<sub>2</sub> inhibits the infection by mutant viral particles.

20



## EXAMPLE 3

A GPG-deleted provirus based on the infectious clone pBRu-2 was constructed using conventional techniques in molecular biology. *Escherichia coli* DH5 $\alpha$  and NM522 mutS were used for sub-cloning, mutagenesis, and amplification of plasmid DNAs. The puc18 plasmid was used as a vector for sub-cloning, and the HIV-1 proviral clone pBRu-2, which contains a full-length, replication-competent clone of HIV-1/Bru (also designated as LAV, LAI), was used to generate mutant virus.

The 2.7-kb *SaI*-to-*Bam*HI fragment from pBRu-2, which encodes the *env* gene, was sub-cloned into the *SaI* and *Bam*HI sites of the puc18 vector. GPG deletion was accomplished by site-directed mutagenesis using the U.S.E. Mutagenesis Kit (Pharmacia). Two oligonucleotides were required. The mutagenic oligonucleotide was 5'-phosphorylated CGT ATC CAG AGG AGA GCA TTT GTT ACA ATA GG-3' (obtained from Scandinavian Gene Synthesis AB, Stockholm, Sweden). The selective oligonucleotide was 5'-phosphorylated GTG CCA CCT GTC GAC TAA GAA ACC AT-3' and was designed to remove a unique restriction site, *Aat*II, in the puc18 vector. The wild-type DNA was, thus, selectively eliminated from the mixed pool of wild-type and mutant DNA by digestion with the corresponding endonuclease *Aat*II. The mutagenesis reaction products were transformed into *E.coli* to amplify the plasmid DNAs. The mutation was verified by Polymerase Chain Reaction (PCR) sequencing of the DNA using an Automated Laser Fluorescent ALF™ DNA Sequencer (Pharmacia). The *SaI*-*Bam*HI fragment deleted from the oligonucleotide encoding GPG was then cloned into pBRu-2 to generate the proviral plasmid. The mutant DNAs from several bacterial colonies were amplified and purified by QIAGEN Plasmid Kit. Two of them, mp8 and mp10 DNAs, were transfected into cells.

The wild-type DNA and the mutant DNA, mp8 and mp10 were transfected into Hela, HUT<sub>78</sub>, or MT-2 cells using DEAE-dextran method. (Palker et al., *Proc. Natl. Acad. Sci. USA* 85: 1932-1936 (1988)). Briefly, 10<sup>6</sup> cells were prepared 24 hours before transfection. Then, the medium was removed and the cells were washed once with pre-warmed phosphate-buffered saline (PBS) and once with TBS-D (Tris buffered saline-0.1% dextrose). Approximately 0.5 $\mu$ g DNA was mixed with TBS-D/DEAE-dextran and was added to the cells followed by a 30 minute incubation at 37°C. Then the solution was removed and the cells were washed once with TBS-D and once with PBS. The cells were mixed with 5ml pre-warmed medium supplemented with 10% serum and 5 $\mu$ g chloroquine diphosphate and were incubated 1 hour at 37°C followed by three times washes with serum-free medium. Finally, the cells were maintained in 10ml culture medium and incubated at 37°C for 4 days.

Virus-containing supernatants were collected, filtered through a 0.45 $\mu$ m pore-size filter to remove any cells, aliquoted and kept at -70°C as virus stock. Titration of virus was performed by infecting MT-2 cells with serial dilutions of virus. One hundred microliters from each five-fold serial dilution of the virus supernatants served as inoculum for 200,000 MT 2 cells. After 16 hours adsorption, the cells were washed five times and resuspended in 1.5ml culture medium in 24-well plates (Costar Corporation). Medium was changed at 4, 7, and 11 days post infection and p24 production in the supernatants was tested on day 14. The 50% tissue culture infectious dose

(TCID<sub>50</sub>) end point was calculated according to the Reed-Muench formula. (Reed and Muench, *Am. J. Hygiene* 27: 493-497 (1938)).

CD4<sup>+</sup> T-cell lines MT-2, C91-PL, C8166, CEM, HUT<sub>78</sub>, H9, Jurkat and Molt-3, monocytic cell lines U937, and THP-1, were propagated and maintained in RPMI1640 medium (GIBCO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (GIBCO), penicillin (100u/ml) and streptomycin (100u/ml). Hela cells were grown in medium 199 with Hank's salt supplemented with 2% FBS, 0.8% dextrose and antibiotics.

Peripheral blood mononuclear cells (PBMCs) were purified by Ficoll-Hypaque density gradient centrifugation and stimulated with phytohemagglutinin (KEBO Lab) for three days in RPMI 1640 medium supplemented as described above before being infected. Dendritic cells (DCs) were generated from blood monocytes that were purified from the mononuclear fraction by adherence to plastic as described by Rormani et al., *J. Exp. Med.* 180:83-93 (1994). In brief, blood mononuclear cells were purified, as described above, and adherence was carried out onto tissue-culture flasks in RPMI medium for two hours, then the non-adherent cells were washed away with PBS. The adherent cells were cultured for seven days in medium with GM-CSF (25 u/ml) and IL-4 (4.5 u/ml) and then were infected with virus.

Infections were performed on cell-lines MT-2, C9 1 -PL, C8166, CEM, HUT<sub>78</sub>, H9, Jurkat, Molt-3, U937, THP-1, PBMCs and dendritic cells (DCs). For CD4<sup>+</sup> cell-lines, 200,000 cells were incubated in 37°C with wild-type or mutant virus at 100 TCID<sub>50</sub> for 16 hours, then washed five times, resuspended in 1.5ml fresh RPMI medium supplemented with 10% FBS, antibiotics and Polybrene (Sigma, 2µg/ml) and incubated in 24-well plate in 37°C in 5% CO<sub>2</sub> with humidity. For PBMCs, 500,000 cells were used and cultured in RPMI medium supplemented with proleukin (Eurocetus, 150u/ml), hydrocortisone (Sigma, 5µg/ml) and polybrene (Sigma, 2µg/ml). For DCs, 800,000 cells were exposed to virus for 1, 16 and 48 hours, respectively followed by 3 times of wash in PBS and gentle treatment of 0.05% trypsin in 37°C for 5 minutes to remove any surface-bound virus, as described by Grannelli-Piperno et al, *J. Exp. Med.* 184:2433-2438 (1996). As a control, PBMCs were exposed to mp8 in the same way. The cells were washed, collected and lysed to isolate DNAs by phenol/chloroform extraction then a semi-quantitative PCR detecting LTR sequence was performed. Ten-fold serial dilutions were made on the DNAs and the LTR PCR was performed in 40 cycles, using a three primer "nested" configuration as described before. (Hwang et al., *Science* 253: 71-74 (1991)). For DC-PBMC co-culture and DC-MT-2 co-culture experiments, 250,000 DCs were exposed to virus for 16 hours followed by five times of washes until no p24 could be detected (less than 5pg/ml). Then the cells were gently treated with 0.05% trypsin that destroys the HIV-1 binding epitope on CD4 and removes any surface-bound virus. After washing, the cells were resuspended in RPMI culture medium mixed with 200,000 PBMCs cells or 100,000 MT-2 cells.

For infection experiments, culture medium was changed at 4, 7, 11, 14 and 17 days post infection and viral growth was determined by p24 levels using an HIV-1 p24 ELISA kit (Abbott Laboratories, North Chicago, USA). The ELISA quantitation of the p24 assay was used to quantitate the level of p24 in each virus sample and this assay had a linear dose-response range from 20pg to 640pg of p24 per ml. All virus samples were assayed at multiple dilutions

and p24 amount was determined with the aid of a regression line. DNAs were isolated from the cells cultured for 17 days post infection and direct sequencing of the V3 region was performed on these DNAs to verify the mutation.

Immunocytochemistry was also performed on infected and uninfected MT-2 cells by an APAAP (Alkaline Phosphatase Anti-Alkaline Phosphatase immunocomplexes) sandwich technique as previously described in Kowalski et al., *Science* 237:1351-1355 (1987). Cells were washed twice in PBS and fixed on slides by acetone for 15 minutes. Then the cells were incubated in succession with the primary antibody mouse anti-HIV-1 p24, the secondary antibody rabbit anti-mouse immunoglobulins, and mouse APAAP monoclonal antibody (DAKO) for 30 minutes at 37°C, respectively, in a humid chamber followed by washing in PBS for 5 minutes. After chromogenic substrate was added and incubated for 20 minutes at room temperature, slides were washed in H<sub>2</sub>O, mounted in glycerol and viewed under microscopy (magnification x100). The monoclonal antibodies (Mabs) mouse anti-HIV-1 p24 (DAKO, diluted 1:20), rabbit anti-mouse immunoglobulins (diluted 1:25) and mouse immunocomplexes of Mab to calf intestinal alkaline phosphatase and calf intestinal alkaline phosphatase (APAAP, diluted 1:20) were used for the immunocytochemistry assay.

Additionally, electron microscopy was performed on infected cells. Freshly infected cells were fixed on day 7 by 2.5% glutaraldehyde and postfixed in 1% OSO<sub>4</sub>. The cells were dehydrated, embedded with epoxy resins and stained with 1% uranyl acetate. Epon sections of virus infected cells were made 60-80nm thin. The specimens were analyzed in a Zeiss CEM 902 at an accelerating voltage of 80kV, which was equipped with a spectrometer to improve image quality. A liquid nitrogen cooling trap was used to reduce beam damage.

In another set of experiments, more evidence that GPG-NH<sub>2</sub> inhibits HIV-1 infection by a mechanism other than V3 loop inhibition was obtained. Accordingly, the ability of GPG-NH<sub>2</sub> to inhibit the infectivity of wild-type and V3-loop deletion mutants (GPG domain) in MT-2 cells was determined. In these experiments, approximately 200,000 MT-2 cells were infected with HIV-1<sub>B<sub>av</sub></sub> wild-type and GPG-deleted mutants mp8 and mp10 at 25 TCID<sub>50</sub> to test the inhibitory effect of GPG-NH<sub>2</sub>. The MT-2 cells were resuspended in 1ml of RPMT 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, GIBCO), penicillin (100μ/ml), streptomycin (100μ/ml) and Polybrene (Sigma 2μg/ml) with or without the presence of GPG-NH<sub>2</sub> at concentration 20 of μM and 100μM. Thereafter, viruses were added at 25 TCID<sub>50</sub> in a volume of 20-30μl. Cells were incubated with virus at 37°C for 16hr then loosely pelleted by centrifugation at 170xg for 7 minutes. The cells were then washed three times in RPMI medium without peptides at room temperature by cell sedimentation at 170xg for 7 minutes as above. After the final wash, the cells were resuspended in RPMI culture medium in 24-well plate (Costar corporation) then kept at 37°C in 5% CO<sub>2</sub> with humidity. Culture supernatants were collected when medium was changed at day 4, 7, 11 and 14 post infection. To monitor the replication of virus, HIV-1 p24 antigen protein in the supernatants from day 7 and 14 was assayed by a ELISA kit (Abbott Laboratories) which has a linear dose-response range from 20pg to 640pg of p24 per ml and the p24 amount can be determined with aid of the regression line.

The results from the experiments described in this example, discussed in greater detail below, verify that GPG-NH<sub>2</sub> inhibits HIV-1 infection in a V3 loop independent manner.

*Small peptides inhibit HIV-1 infection in a V3 loop independent manner*

To determine if the GPG-deletion in the V3 loop affected the production of virus, the proviral plasmid DNAs (both wild-type and mutant) were transfected into the CD4 negative cell line Hela, as well as, the CD4 positive cell lines MT-2 and HUT<sub>78</sub>. Culture supernatants were collected every day and virus production was monitored by measuring p24 levels. A similar growth pattern was observed for the wild-type virus (WT) and the mutants from Hela transfections, within a 6-day time frame. The p24 levels kept increasing until day 4, then stayed on a plateau. Hence, both the mutant and the wild-type proviral DNAs were equally well expressed in these cells. Similar results were obtained from HUT<sub>78</sub>, transfectants and syncytia were observed in these transfected HUT<sub>78</sub> cells. The pattern of p24 production from MT-2 transfections, however, were notably different from those observed in Hela and HUT78 cells. The p24 product level kept increasing beyond day four although the p24 production of cells transfected with the mutant virus proviral DNAs were lower than those transfected with the wild-type virus proviral DNA. On day 6 post transfection, the wild-type produced 1,380ng/ml of p24 while the p24 production of mp8 and mp10 were 15.8ng/ml and 13.7ng/ml, respectively. These results demonstrate that GPG-deleted mutant progeny viruses were produced and could infect non-transfected CD4+ MT-2 cells, albeit apparently not as efficiently as did wild-type progeny. DNAs from these transfected cells were sequenced and the GPG deletion was verified for both the mp8 and the mp10 progeny.

Next, the ability of the mutant molecular clones to generate virus particles capable of establishing an infection was further analyzed. Hela cells and MT-2 cells were transfected with the proviral DNAs and four days post transfection the culture supernatants were collected, filtered, assayed for p24 levels and aliquots were frozen at -70°C as virus stocks. Viral titration (TCID<sub>50</sub>) was performed on MT-2 cells. Supernatants from MT-2 transfectants, adjusted to contain the same amount of p24, the wild-type virus yielded 83,300 TCID<sub>50</sub>/ml whereas the mutants, mp8 and mp10 yielded 16,700 and 25,000 TCID<sub>50</sub>/ml, respectively -- about five fold less than what was obtained with the wild-type virus. In concordance with a lower p24 production of the Hela transfectant supernatants, the titers they yielded were also much lower, 70 and 10 TCID<sub>50</sub>/ml for WT and mutants respectively. Thus, although the mutant virus was still infectious, deletion of the GPG motif in V3 may have reduced the viral virulence in these cells. This was further tested by infection of MT-2 cells and monitored the production of progeny virus. The virus stocks from both Hela and MT-2 transfections were then used to infect MT-2 cells (100 TCID<sub>50</sub> wild type or mutant virus from MT-2 transfectant supernatants, or five TCID<sub>50</sub> of Virus from Hela transfectant stocks). The cells were incubated with virus for 16 hours and then washed. Thereafter, the cells were resuspended and incubated at 37°C. Virus replication was monitored by measuring p24 levels and cytopathic effects. With virus from MT-2 transfectants, wild-type (WT), as well as, the mutant virus (mp8 and mp10), all showed viral replication by p24 production. Wild-type reached peak p24 levels of 2,150ng/ml at day 11 post infection while the mutant viruses exhibited approximately a 4-day delay, with peak p24 values of 1,580ng/ml and 1,760ng/ml for mp8 and mp10, respectively at day 14 post infection. Infections of MT-2 cells with virus from Hela transfectants (at 5 TCID<sub>50</sub>) also yielded p24 production of both the WT and the mutants with similar growth kinetics as those obtained with MT-2 cell produced virus. DNAs were isolated from all

infected cells and the mutation was verified by V3 sequencing, indicating that the growth of the mutant virus was not due to reversion to or pick up of the wild-type sequence.

Syncytium formation was also observed in the MT-2 cells infected with both the WT and the mutants. Cell cultures were fixed at day 7 post infection and was used for immunocytochemistry using the APAAP sandwich technique. The infected cells were immunostained and gave a red color. Syncytia were observed in both WT and mutant virus infected MT-2 cells, although WT virus induced syncytia earlier (4 days post infection) than the mutants (after 6 days). Electron microscopy (EM) further revealed that the mutant virus infected MT-2 cells produced HIV-1 particles. HIV-1 particles, having a characteristic cone-shaped core, were seen. These data confirmed that the GPG-deletion mutant virus remained infectious in MT-2 cells.

Conclusive evidence that GPG-NH<sub>2</sub> inhibits viral infection by a mechanism different than a V3 loop interaction was obtained when experiments that assessed the ability of GPG-NH<sub>2</sub> to inhibit the infectivity of wild-type and V3-loop deletion mutants (GPG domain) in MT-2 cells were performed. At both 7 days and 14 days after infection, a considerable reduction in wild type and mutant viral infection was seen. See Table 10. At 20μM and 100μM, GPG-NH<sub>2</sub> effectively reduced wild type infection and infection mediated by the GPG deletion constructs mp8 and mp10. In fact, at 7 days post infection and 100μM GPG-NH<sub>2</sub>, an equally complete reduction of viral infectivity was observed for wild-type, mp8, and mp10. These results established that GPG-NH<sub>2</sub> was inhibiting HIV-1 infection by a mechanism independent from an interaction with the GPG domain of the V3 loop.

TABLE 10

Day 7	p24 pg/ml				
	control	GPG 20μM	reduction %	GPG 100μM	reduction %
WT	33800	23900	29	3390	90
mp8	3170	2420	24	208	93
mp10	3120	1560	50	173	94

Day 14					
WT	357000	223000	38	181000	49
mp8	148000	69100	53	7410	95
mp10	470000	51500	89	47700	90

20

The data presented herein establish that small peptides having a modified carboxy terminus inhibit viral infection (e.g., HIV-1, HIV-2, and SIV infection), bind to p24, and interrupt proper capsid assembly. The many assays detailed above can be used to identify the ability of any small peptide, modified small peptide, oligopeptide, or peptidomimetic to prevent or inhibit HIV or SIV infection. Similar techniques can also be used to identify the ability of any small peptide, modified small peptide, oligopeptide, or peptidomimetic to prevent or inhibit other viral infections.

Because the sequence of several viral capsid proteins are known, the design, manufacture, and identification of small peptides in amide form that prevent proper assembly of different viral capsids is straightforward. Several

viral capsid proteins, for instance, contain a 20 amino acid long homology region called the major homology region (MHR), that exists within the carboxyl-terminal domain of many onco- and lentiviruses. (See Figure 5). Figure 5 shows the carboxyl-terminal domain of HIV-1 (residues 146-231) and compares this sequence to the capsid protein sequences of other viruses, some of which infect birds, mice, and monkeys. Notably, considerable homology in the sequences of these viral capsid proteins is found. Investigators have observed that the carboxyl-terminal domain is required for capsid dimerization and viral assembly in HIV-1. (Gamble et al., *Science* 278: 849 (1997), herein incorporated by reference in its entirety). While the small peptides that exhibited antiviral activity in the assays described in this disclosure fully or partially corresponded to regions of the carboxyl-terminal domain of HIV-1, HIV-2, or SIV, regions of the N-terminal domain of viruses are important for capsid assembly and the design and synthesis of small peptides that either fully or partially correspond to amino acids of the N-terminal region of viral capsid proteins are desirable embodiments of the present invention. The use of small peptides that fully or partially correspond to amino acids within the MHR region and the carboxyl-terminal domain of viral capsid proteins, however, are preferred embodiments of the present invention.

The inventor has shown several novel small peptides in amide form that fully or partially correspond to to capsid protein sequence of three different viruses effectively inhibit and/or prevent infection by these viruses. The strategies employed herein can be used to produce additional small peptides in amide form that fully or partially correspond to the capsid protein sequences of other viruses. By designing and manufacturing small peptides, oligopeptides, and/or peptidomimetics that correspond to regions of the sequences disclosed in Figure 5, for example, new molecules that inhibit HIV, SIV, RSV, HTLV-1, MMTV, MPMV, and MMLV infection can be rapidly identified by using the screening techniques discussed above or modifications of these assays, as would be apparent to one of skill in the art. Further, many of the sequences of other viral capsid proteins are known, such as members of the arenavirus, rotavirus, orbivirus, retrovirus, papillomavirus, adenovirus, herpesvirus, paramyxovirus, myxovirus, and hepadnavirus families. Several small peptides, oligopeptides, and/or peptidomimetics that fully or partially correspond to these sequences can be selected and rapidly screened to identify those that effectively inhibit and/or prevent viral infection by using the viral infectivity assays and/or electron microscopy techniques described herein, or modifications of these assays as would be apparent to those of skill in the art given the present disclosure.

Desirable embodiments include small peptides (more than one amino acid and less than or equal to 10 amino acids in length) having a modified carboxy terminus that are used to interrupt capsid assembly and inhibit viral infection. Preferably, dipeptides, tripeptides, and oligopeptides and corresponding peptidomimetics having a sequence that is found in the HIV or SIV capsid are used. For example, an oligopeptide of the present invention may have four amino acids, five amino acids, six amino acids, seven amino acids, eight, or nine or ten amino acids and peptidomimetics of the present invention may have structures that resemble four, five, six, seven, eight, nine, or ten amino acids. These oligopeptides also desirably include the full or partial sequences found in the tripeptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>. Peptidomimetics that resemble dipeptides, tripeptides and oligopeptides also, preferably, correspond to a sequence

that is found in GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>. It is preferred that the small peptides possess a modulation group (e.g., an amide group) at their carboxy termini (CO-NH<sub>2</sub>) rather than a carboxyl group (COOH). Small peptides having other modulation groups at the carboxy terminus, can also be used but desirably, the attached modulation groups have the same charge and sterically behave the same as an amide group. (See U.S. Patent No. 5,627,035 to Vahlne et al., for an assay to compare peptides having differing substituents at the carboxyl terminus). In some embodiments, the addition of an acetyl or methyl group at either end of a small peptide is desirable so as to improve uptake of the small peptide or prevent exo-protease digestion or both.

In the following disclosure, several approaches are provided to make biotechnological tools and pharmaceutical compositions comprising dipeptides, tripeptides, oligopeptides of less than or equal to 10 amino acids, and peptidomimetics that resemble tripeptides and oligopeptides of less than or equal to 10 amino acids (collectively referred to as a "peptide agent(s)"). It should be noted that the term "peptide agents" includes dipeptides, tripeptides, and oligopeptides of less than equal to 10 amino acids. "Peptide agents" are, for example, peptides of two, three, four, five, six, seven, eight, nine, or ten amino acids and peptidomimetics that resemble peptides of two, three, four, five, six, seven, eight, nine, or ten amino acids. Further, "peptide agents" are peptides of two, three, four, five, six, seven, eight, nine, or ten amino acids or peptidomimetics that resemble two, three, four, five, six, seven, eight, nine, or ten amino acids that are provided as multimeric or multimerized agents, as described below.

Desirable biotechnological tools or components to prophylactic or therapeutic agents, provide the peptide agent in such a form or in such a way that a sufficient affinity or inhibition of a virus, such as HIV-1, HIV-2, or SIV, is obtained. While a natural monomeric peptide agent (e.g., appearing as discrete units of the peptide agent each carrying only one binding epitope) is sufficient to bind a capsomere protein, such as p24, and/or interfere with capsid assembly and/or prevent viral infection, such as HIV-1, HIV-2, or SIV infection, synthetic ligands or multimeric ligands (e.g., appearing as multiple units of the peptide agent with several binding epitopes) may have far greater ability to bind a capsomere protein, such as p24, and/or interfere with capsid assembly and/or prevent viral infection, such as HIV-1, HIV-2, or SIV infection. It should be noted that the term "multimeric" is meant to refer to the presence of more than one unit of a ligand, for example several individual molecules of a tripeptide, oligopeptide, or a peptidomimetic, as distinguished from the term "multimerized" that refers to the presence of more than one ligand joined as a single discrete unit, for example several tripeptides, oligopeptides, or peptidomimetic molecules joined in tandem.

#### *Preparation of multimeric supports and multimerized ligands*

A multimeric agent (synthetic or natural) that binds a capsomere protein, such as p24, and/or interferes with capsid assembly and/or inhibits viral infection, such as HIV-1, HIV-2, or SIV infection, may be obtained by coupling a tripeptide, oligopeptide or a peptidomimetic to a macromolecular support. The term "support" as used herein includes a carrier, a resin or any macromolecular structure used to attach, immobilize, or stabilize a peptide agent. Solid supports include, but are not limited to, the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells,

artificial cells and others. The term Support also includes carriers as that term is understood for the preparation of pharmaceuticals.

The macromolecular support may have a hydrophobic surface that interacts with a portion of the peptide agent by hydrophobic non-covalent interaction. The hydrophobic surface of the support may also be a polymer such as plastic or any other polymer in which hydrophobic groups have been linked such as polystyrene, polyethylene or polyvinyl. Alternatively, the peptide agent can be covalently bound to carriers including proteins and oligo/polysaccharides (e.g. cellulose, starch, glycogen, chitosane or aminated sepharose). In these later embodiments, a reactive group on the peptide agent, such as a hydroxy or an amino group, may be used to join to a reactive group on the carrier so as to create the covalent bond. The support may also have a charged surface that interacts with the peptide agent. Additionally, the support may have other reactive groups that can be chemically activated so as to attach a peptide agent. For example, cyanogen bromide activated matrices, epoxy activated matrices, thio and thiopropyl gels, nitrophenyl chloroformate and N-hydroxy succinimide chloroformate linkages, and oxirane acrylic supports are common in the art.

The support may also comprise an inorganic carrier such as silicon oxide material (e.g. silica gel, zeolite, diatomaceous earth or aminated glass) to which the peptide agent is covalently linked through a hydroxy, carboxy or amino group and a reactive group on the carrier. Furthermore, in some embodiments, a liposome or lipid bilayer (natural or synthetic) is contemplated as a support and peptide agents are attached to the membrane surface or are incorporated into the membrane by techniques in liposome engineering. By one approach, liposome multimeric supports comprise a peptide agent that is exposed on the surface of the bilayer and a second domain that anchors the peptide agent to the lipid bilayer. The anchor may be constructed of hydrophobic amino acid residues, resembling known transmembrane domains, or may comprise ceramides that are attached to the first domain by conventional techniques.

Supports or carriers for use in the body, (i.e. for prophylactic or therapeutic applications) are desirably physiological, non-toxic and preferably, non-immunoresponsive. Contemplated carriers for use in the body include poly-L-lysine, poly-D, L-alanine, liposomes, and Chromosorb\* (Johns-Manville Products, Denver Co.). Ligand conjugated Chromosorb\* (Synsorb-Pk) has been tested in humans for the prevention of hemolytic-uremic syndrome and was reported as not presenting adverse reactions. (Armstrong et al *J. Infectious Diseases*, 171:1042-1045 (1995)). For some embodiments, the present inventor contemplates the administration of a "naked" carrier (i.e., lacking an attached peptide agent) that has the capacity to attach a peptide agent in the body of a subject. By this approach, a "prodrug-type" therapy is envisioned in which the naked carrier is administered separately from the peptide agent and, once both are in the body of the subject, the carrier and the peptide agent are assembled into a multimeric complex.

The insertion of linkers, such as  $\lambda$  linkers, of an appropriate length between the peptide agent and the support are also contemplated so as to encourage greater flexibility of the peptide agent and thereby overcome any steric hindrance that may be presented by the support. The determination of an appropriate length of linker that allows for optimal binding to a capsomere protein, such as p24, and/or interference with capsid assembly and/or



inhibition of viral infection, such as HIV or SIV infection, can be determined by screening the peptide agents with varying linkers in the assays detailed in the present disclosure.

A composite support comprising more than one type of peptide agent is also an embodiment. A "composite support" may be a carrier, a resin, or any macromolecular structure used to attach or immobilize two or more different peptide agents that bind to a capsomere protein, such as p24, and/or interfere with capsid assembly and/or inhibit viral infection, such as HIV or SIV infection. In some embodiments, a liposome or lipid bilayer (natural or synthetic) is contemplated for use in constructing a composite support and peptide agents are attached to the membrane surface or are incorporated into the membrane using techniques in liposome engineering.

As above, the insertion of linkers, such as  $\lambda$  linkers, of an appropriate length between the peptide agent and the support is also contemplated so as to encourage greater flexibility in the molecule and thereby overcome any steric hindrance that may occur. The determination of an appropriate length of linker that allows for optimal binding to a capsomere protein, such as p24, and/or interference with capsid assembly and/or inhibition of viral infection, such as HIV or SIV infection, can be determined by screening the ligands with varying linkers in the assays detailed in the present disclosure.

In other embodiments of the present invention, the multimeric and composite supports discussed above may have attached multimerized ligands so as to create a "multimerized-multimeric support" and a "multimerized-composite support", respectively. A multimerized ligand may, for example, be obtained by coupling two or more peptide agents in tandem using conventional techniques in molecular biology. The multimerized form of the ligand may be advantageous for many applications because of the ability to obtain an agent with a better ability to bind to a capsomere protein, such as p24, and/or interfere with capsid assembly and/or inhibit viral infection, such as HIV or SIV infection. Further, the incorporation of linkers or spacers, such as flexible  $\lambda$  linkers, between the individual domains that make-up the multimerized agent is an advantageous embodiment. The insertion of  $\lambda$  linkers of an appropriate length between protein binding domains, for example, may encourage greater flexibility in the molecule and can overcome steric hindrance. Similarly, the insertion of linkers between the multimerized ligand and the support may encourage greater flexibility and limit steric hindrance presented by the support. The determination of an appropriate length of linker that allows for optimal binding to p24 and/or interference with capsid assembly and/or inhibition of HIV or SIV infection, can be determined by screening the ligands with varying linkers in the assays detailed in this disclosure.

In preferable embodiments, the various types of supports discussed above are created using the tripeptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>.

The multimeric supports, composite supports, multimerized-multimeric supports, or multimerized-composite supports, collectively referred to as "support-bound agents", are also preferably constructed using the tripeptides GPG-NH<sub>2</sub>, GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>.

In the discussion below, several embodiments of the invention that have therapeutic and/or prophylactic application are described.

*Therapeutic and prophylactic applications*

The monomeric and multimeric peptide agents described herein are suitable for treatment of subjects either as a preventive measure to avoid viral infections, such as HIV or SIV infection, or as a therapeutic to treat subjects already infected with a virus, such as HIV or SIV. Although anyone could be treated with the peptides as a prophylactic, the most suitable subjects are people at risk for viral infection. Such subjects include, but are not limited to, homosexuals, prostitutes, intravenous drug users, hemophiliacs, children born to virus-infected mothers, and those in the medical profession who have contact with patients or biological samples.

The pharmacologically active compounds of this invention can be processed in accordance with conventional methods of galenic pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. The peptide agents can be incorporated into a pharmaceutical product with and without modification. Further, the manufacture of pharmaceuticals or therapeutic agents that deliver the peptide agent or a nucleic acid sequence encoding a small peptide by several routes is an embodiment. For example, and not by way of limitation, DNA, RNA, and viral vectors having sequence encoding a small peptide that inhibits viral replication by interrupting capsid assembly are contemplated. Nucleic acids encoding a desired peptide agent can be administered alone or in combination with peptide agents.

The compounds described herein can be employed in admixture with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, enteral (e.g., oral) or topical application that do not deleteriously react with the peptide agents. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like that do not deleteriously react with the active compounds. They can also be combined where desired with other active agents, e.g., vitamins.

In some embodiments, therapeutic agents comprising peptide agents are administered in conjunction with other therapeutic agents that treat viral infections, such as HIV infection, so as to achieve a better viral response. At present four different classes of drugs are in clinical use in the antiviral treatment of HIV-1 infection in humans. These are (i) nucleoside analogue reverse transcriptase inhibitors (NRTIs), such as zidovudine, lamivudine, stavudine, didanosine, abacavir, and zalcitabine; (ii) nucleotide analogue reverse transcriptase inhibitors, such as didanosine and pivalaxir; (iii) non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, nevirapine, and delavirdine; and (iv) protease inhibitors, such as indinavir, nelfinavir, zalcitabine, saquinavir and amprenavir. By simultaneously using two, three, or four different classes of drugs in conjunction with administration of the peptide agents, HIV is less likely to develop resistance, since it is less probable that multiple mutations that overcome the different classes of drugs and the peptide agents will appear in the same virus particle.

It is thus a preferred embodiment of the present invention that peptide agents be given in combination with nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors at doses and by methods known to those of skill in the art. Medicaments comprising the peptide agents and nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors are also embodiments of the present invention.

Studies on the efficacy of treatment of HIV infection with combinations of GPG-NH<sub>2</sub> and conventional antiviral agents can be found in the example provided below.

#### EXAMPLE 4

In this example, experiments are presented in which different combinations of a small peptide in amide form and AZT were tested to determine whether the two compounds could complement one another to inhibit HIV-1 replication. (See Figure 6). Accordingly, 200,000 HUT<sub>78</sub> cells were infected with HIV-1 SF-2 virus at 25 TCID<sub>50</sub>, with or without the presence of different concentrations of GPG-NH<sub>2</sub>, AZT or Ritonavir ("Rito") and combinations of these compounds. The numbers shown in Figure 6 represent micromolar concentrations of the inhibiting compounds. Cells were incubated with virus at 37°C for 1 hr with the various inhibitors and were subsequently washed three times. Next, the cells were resuspended in RPMI 1640 medium containing the antiviral agent and/or the peptides supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, GIBCO), penicillin (100u/ml), streptomycin (100u/ml) and Polybrene (Sigma, 2µg/ml) and cultured in 24-well plate (Costar corporation) at 37°C in 5% CO<sub>2</sub> with humidity. Culture supernatants were collected every four days and medium was changed until day 14 post infection. To monitor the replication of virus, HIV-1 p24 antigen protein in the supernatants was assayed using a commercially available kit (Abbott).

It was observed that GPG-NH<sub>2</sub> enhanced the inhibition of the replication of HIV-1 in the presence of AZT synergistically, whereas, the small peptide only exhibited an additive antiviral effect to that of the protease inhibitor Ritonavir. Nevertheless, these experiments validate data presented above that small peptides inhibit HIV-1 by a mechanism apart from the manner in which nucleoside analogs and protease inhibitors interfere with viral replication. Further, these experiments demonstrate that a novel treatment protocol for HIV-1 infection comprising small peptides and AZT and/or Ritonavir is efficacious.

In the following disclosure, doses and methods of administration are provided.

#### *Dosage and methods of administration*

The effective dose and method of administration of a particular peptide agent formulation may vary based on the individual patient and the stage of the disease, as well as other factors known to those of skill in the art. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions that exhibit large therapeutic indices are

WHAT IS CLAIMED IS:

1. A composition for inhibiting viral replication in host cells infected with a virus, comprising an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>, and wherein said composition inhibits viral replication by interrupting viral capsid assembly.
2. The composition of Claim 1, wherein the peptide is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.
3. The composition of Claim 1, wherein  $X_3$  is glycine.
4. The composition of Claim 1, wherein the peptide in amide form has the formula  $X_4X_5X_1X_2X_3\text{-NH}_2$ , wherein  $X_4$  and  $X_5$  are any amino acid and, wherein any one or two amino acids is absent.
5. The composition of Claim 1, wherein the tripeptide  $X_1X_2X_3$  is found in the amino acid sequence of the capsid protein of the virus.
6. The composition of Claim 1, wherein the peptide is joined to a support.
7. The composition of Claim 1, wherein the peptide is incorporated into a pharmaceutical comprising a pharmaceutically acceptable carrier.
8. A peptide in amide form having the formula Gly-Lys-Gly-NH<sub>2</sub>.
9. The peptide of Claim 8 joined to a support.
10. A peptide in amide form having the formula Arg-Gln-Gly-NH<sub>2</sub>.
11. The peptide of Claim 10 joined to a support.
12. A peptide in amide form having the formula Cys-Gln-Gly-NH<sub>2</sub>.
13. The peptide of Claim 12 joined to a support.
14. A peptide in amide form having the formula Lys-Gln-Gly-NH<sub>2</sub>.
15. The peptide of Claim 14 joined to a support.
16. A peptide in amide form having the formula Ala-Leu-Gly-NH<sub>2</sub>.
17. The peptide of Claim 16 joined to a support.
18. A peptide in amide form having the formula Ser-Leu-Gly-NH<sub>2</sub>.
19. The peptide of Claim 18 joined to a support.
20. A method of inhibiting HIV replication in a host cell comprising:  
administering to said cell an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>.
21. The method of Claim 20, wherein the peptide is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

5           The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Additional factors that may be taken into account include the severity of the disease state, age, weight and gender of the patient; diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Short acting pharmaceutical compositions are administered daily whereas long acting  
10       pharmaceutical compositions are administered every 2, 3 to 4 days, every week, or once every two weeks. Depending on half-life and clearance rate of the particular formulation, the pharmaceutical compositions of the invention are administered once, twice, three, four, five, six, seven, eight, nine, ten or more times per day.

          Normal dosage amounts may vary from approximately 1 to 100,000 micrograms, up to a total dose of about 10 grams, depending upon the route of administration. Desirable dosages include 250 $\mu$ g, 500 $\mu$ g, 1mg, 50mg,  
15       100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, 850mg, 900mg, 1g, 1.1g, 1.2g, 1.3g, 1.4g, 1.5g, 1.6g, 1.7g, 1.8g, 1.9g, 2g, 3g, 4g, 5, 6g, 7g, 8g, 9g, and 10g. Additionally, the concentrations of the peptide agents can be quite high in embodiments that administer the agents in a topical form. Molar concentrations of peptide agents can be used with some embodiments. Desirable concentrations for topical administration and/or for coating medical equipment range from 100 $\mu$ M to 800mM.  
20       Preferable concentrations for these embodiments range from 500 $\mu$ M to 500mM. For example, preferred concentrations for use in topical applications and/or for coating medical equipment include 500 $\mu$ M, 550 $\mu$ M, 600 $\mu$ M, 650 $\mu$ M, 700 $\mu$ M, 750 $\mu$ M, 800 $\mu$ M, 850 $\mu$ M, 900 $\mu$ M, 1mM, 5mM, 10mM, 15mM, 20mM, 25mM, 30mM, 35mM, 40mM, 45mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM, 180mM, 190mM, 200mM, 325mM, 350mM, 375mM, 400mM, 425mM, 450mM, 475mM, and  
25       500mM. Guidance as to particular dosages and methods of delivery is provided in the literature, (see e.g., U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212) and below.

          More specifically, the dosage of the peptide agents described herein is one that provides sufficient peptide agent to attain a desirable effect including binding of a capsomere protein, such as p24, and/or interference with capsid assembly and/or inhibition of viral infection, such as HIV and SIV infection. Accordingly, the dose of peptide  
30       agent preferably produces a tissue or blood concentration or both from approximately 0.1  $\mu$ M to 500mM. Desirable doses produce a tissue or blood concentration or both of about 1 to 800  $\mu$ M. Preferable doses produce a tissue or blood concentration of greater than about 10  $\mu$ M to about 500 $\mu$ M. Preferable doses are, for example, the amount of small peptide required to achieve a tissue or blood concentration or both of 10 $\mu$ M, 15 $\mu$ M, 20 $\mu$ M, 25 $\mu$ M, 30 $\mu$ M, 35 $\mu$ M, 40 $\mu$ M, 45 $\mu$ M, 50 $\mu$ M, 55 $\mu$ M, 60 $\mu$ M, 65 $\mu$ M, 70 $\mu$ M, 75 $\mu$ M, 80 $\mu$ M, 85 $\mu$ M, 90 $\mu$ M, 95 $\mu$ M, 100 $\mu$ M,  
35       110 $\mu$ M, 120 $\mu$ M, 130 $\mu$ M, 140 $\mu$ M, 145 $\mu$ M, 150 $\mu$ M, 160 $\mu$ M, 170 $\mu$ M, 180 $\mu$ M, 190 $\mu$ M, 200 $\mu$ M, 220 $\mu$ M, 240 $\mu$ M,

250 $\mu$ M, 260 $\mu$ M, 280 $\mu$ M, 300 $\mu$ M, 320 $\mu$ M, 340 $\mu$ M, 360 $\mu$ M, 380 $\mu$ M, 400 $\mu$ M, 420 $\mu$ M, 440 $\mu$ M, 460 $\mu$ M, 480 $\mu$ M, and 500 $\mu$ M. Although doses that produce a tissue concentration of greater than 800 $\mu$ M are not preferred, they can be used with some embodiments of the present invention. A constant infusion of the peptide can also be provided so as to maintain a stable concentration in the tissues as measured by blood levels.

5 Higher tissue concentrations can be maintained without harm due to the low toxicity of the peptides. Attempts to select small peptide resistant strains of HIV-1 (e.g., GPG-NH<sub>2</sub> resistant strains) have so far been unsuccessful. The HIV-1 strain HTLV-III<sub>B</sub> was passaged in the presence of serial dilutions of GPG-NH<sub>2</sub> (limiting dilutions) for more than six months without overt signs of development of resistance *in vitro*.

Routes of administration of the peptide agents include, but are not limited to, topical, transdermal, 10 parenteral, gastrointestinal, transbronchial, and transalveolar. Topical administration is accomplished via a topically applied cream, gel, rinse, etc. containing a peptide. Transdermal administration is accomplished by application of a cream, rinse, gel, etc. capable of allowing the peptide agent to penetrate the skin and enter the blood stream. Parenteral routes of administration include, but are not limited to, electrical or direct injection such as direct injection into a central venous line, intravenous, intramuscular, intraperitoneal or subcutaneous injection. Gastrointestinal 15 routes of administration include, but are not limited to, ingestion and rectal. Transbronchial and transalveolar routes of administration include, but are not limited to, inhalation, either via the mouth or intranasally.

Compositions of peptide agent-containing compounds suitable for topical application include, but are not limited to, physiologically acceptable implants, ointments, creams, rinses, and gels. Any liquid, gel, or solid, pharmaceutically acceptable base in which the peptides are at least minimally soluble is suitable for topical use in the present invention. 20 Compositions for topical application are particularly useful during sexual intercourse to prevent transmission of HIV. Suitable compositions for such use include, but are not limited to, vaginal or anal suppositories, creams, and douches.

Compositions of the peptide agents suitable for transdermal administration include, but are not limited to, pharmaceutically acceptable suspensions, oils, creams, and ointments applied directly to the skin or incorporated into a protective carrier such as a transdermal device ("transdermal patch"). Examples of suitable creams, ointments, etc. 25 can be found, for instance, in the Physician's Desk Reference and are well known in the art. Examples of suitable transdermal devices are described, for instance, in U.S. Patent No. 4,818,540 issued April 4, 1989 to Chinen, et al., herein incorporated by reference.

Compositions of the peptide agents suitable for parenteral administration include, but are not limited to, pharmaceutically acceptable sterile isotonic solutions. Such solutions include, but are not limited to, saline and 30 phosphate buffered saline for injection into a central venous line, intravenous, intramuscular, intraperitoneal, or subcutaneous injection of the peptide agents.

Compositions of the peptide agents suitable for transbronchial and transalveolar administration include, but not limited to, various types of aerosols for inhalation. For instance, pentamidine is administered intranasally via aerosol to AIDS patients to prevent pneumonia caused by *pneumocystis carinii*. Devices suitable for transbronchial 35 and transalveolar administration of the peptides are also embodiments. Such devices include, but are not limited to,

atomizers and vaporizers. Many forms of currently available atomizers and vaporizers can be readily adapted to deliver peptide agents.

Compositions of the peptide agents suitable for gastrointestinal administration include, but not limited to, pharmaceutically acceptable powders, pills or liquids for ingestion and suppositories for rectal administration. Due to the most common routes of HIV infection and the ease of use, gastrointestinal administration, particularly oral, is the preferred embodiment of the present invention. Five-hundred milligram capsules having a tripeptide (GPG-NH<sub>2</sub>) have been prepared and were found to be stable for a minimum of 12 months when stored at 4 °C. As previously shown in other virus-host systems, specific antiviral activity of small peptides can be detected in serum after oral administration. (Miller et al., *Appl. Microbiol.*, 16:1489 (1968)). Since small peptides apparently evade degradation by the patient's digestive system, they are ideal for oral administration.

The peptide agents are also suitable for use in situations where prevention of HIV infection is important. For instances, medical personnel are constantly exposed to patients who may be HIV positive and whose secretions and body fluids contain the HIV virus. Further, the peptide agents can be formulated into antiviral compositions for use during sexual intercourse so as to prevent transmission of HIV. Such compositions are known in the art and also described in international application published under the PCT publication number W090/04390 on May 3, 1990 to Modak et al., which is incorporated herein by reference in its entirety.

Aspects of the invention also include a coating for medical equipment such as gloves, sheets, and work surfaces that protects against HIV transmission. Alternatively, the peptide agents can be impregnated into a polymeric medical device. Particularly preferred are coatings for medical gloves and condoms. Coatings suitable for use in medical devices can be provided by a powder containing the peptides or by polymeric coating into which the peptide agents are suspended. Suitable polymeric materials for coatings or devices are those that are physiologically acceptable and through which a therapeutically effective amount of the peptide agent can diffuse. Suitable polymers include, but are not limited to, polyurethane, polymethacrylate, polyamide, polyester, polyethylene, polypropylene, polystyrene, polytetrafluoroethylene, polyvinyl-chloride, cellulose acetate, silicone elastomers, collagen, silk, etc. Such coatings are described, for instance, in U.S. Patent No. 4,612,337, issued September 16, 1986 to Fox et al. that is incorporated herein by reference in its entirety.

In the disclosure below, several toxicological studies on small peptides are provided and approaches to test the toxicity of other peptide agents are disclosed.

#### *Small peptide toxicology studies*

Several toxicology studies on GPG-NH<sub>2</sub> have been performed and these assays can be reproduced using many more peptides (e.g., GKG-NH<sub>2</sub>, CQG-NH<sub>2</sub>, RQG-NH<sub>2</sub>, KQG-NH<sub>2</sub>, ALG-NH<sub>2</sub>, GVG-NH<sub>2</sub>, VGG-NH<sub>2</sub>, ASG-NH<sub>2</sub>, SLG-NH<sub>2</sub>, and SPT-NH<sub>2</sub>). (See e.g., U.S. Patent No. 5,627,035 to Vahne et al.). The effects of GPG-NH<sub>2</sub> on cultured lymphocytes is provided in the following example.

## EXAMPLE 5

In this example, several toxicology studies that addressed the effects of small peptides on cultured lymphocytes are presented. Generally, none of the peptides used in the virus inhibition assays for HIV-1 tested at concentrations up to 2 mM exhibited any toxic effect on the cells used, as determined by their morphological appearance, trypan blue staining and cell growth. The toxicity of GPG-NH<sub>2</sub> was further tested in (i) a plaque reduction assay and (ii) a yield inhibition assay of HSV-1. GPG-NH<sub>2</sub> failed to reduce HSV-1 replication at concentrations up to 1 mM that not only confirmed its lack of toxicity but also demonstrated that the small peptide selectively inhibits HIV-related viruses. This view was reinforced by the observation that GPG-NH<sub>2</sub> also failed inhibit either influenza or polio viruses.

Next, the toxicity to normal human lymphomonocytic cells (PBMC) was examined. At doses as high as 2 mM and exposure as long as 4 days, GPG-NH<sub>2</sub> did not appreciably affect the viability of cultured monocytes and lymphocytes. The effect of GPG-NH<sub>2</sub> on *in vitro* proliferative response of human mononuclear cells was also tested. GPG-NH<sub>2</sub> exerted marginal if any direct anti-proliferative properties on T cells and did not affect the function of accessory cells (e.g. monocytes and dendritic cells) at a dose of 20  $\mu$ M.

The *in vitro* 50% cytotoxic concentrations (CC<sub>50</sub>) of various cell lines was also assessed. Accordingly, different concentrations of GPG-NH<sub>2</sub>, up to 40mM, was supplemented into the medium culture of T-cell lines HUT78, H9, CEM-SS, MT-2 and (non) induced ACH-2, as well as, the macrophage derived cell lines Jurkat-tat III, THP-1 and (non) induced U-1 cells. After 3 days of incubation, the number of cells were counted. Trypan-blue dye exclusion and cell counting of HUT78, MT-2 and Jurkat-tat III showed about a 40% inhibition of cell growth for 3 days of culture in the presence of 40mM GPG-NH<sub>2</sub>. H9, CEM-SS, and THP-1 showed a less than 20% decrease in cell number at this GPG-NH<sub>2</sub> concentration. Therefore, the ratio of CC<sub>50</sub>/IC<sub>50</sub> *in vitro* is  $> 10^4$ . The toxicology experiments presented above prove that small peptides are of low toxicity to lymphocytes even at high concentrations.

The effects of large doses of small peptide on rodents was also analyzed and these experiments are presented in the next example.

## EXAMPLE 6

In this example, the results from several *in vivo* toxicology studies on small peptides administered in large doses to rodents are presented. In a first experiment, a large single dose of small peptide was delivered to mice and the toxic effects were analyzed. An intravenous injection of GPG-NH<sub>2</sub> in the tail vein of adult mice at concentrations of up to 1g per kilo bodyweight gave no apparent toxic effects to the animals. In a second experiment, several doses of varying amounts of a small peptide were delivered to mice for almost three weeks. Groups of mice (five mice in each group) were given intraperitoneal injections of GPG-NH<sub>2</sub> (0.01, 0.1 and 1g per kilo bodyweight and day, respectively) starting at an age of 6 days. Daily injections were continued for 18 days. Compared to controls, there was no significant influence of GPG-NH<sub>2</sub> on the mice. In a similar experiment, a four week toxicology study of GPG-NH<sub>2</sub> was performed by Scantox A/S in Denmark. GPG-NH<sub>2</sub> was given orally to rats at doses up to 1 g per kilo bodyweight per day for twenty eight days. No signs of toxicity to the animals was observed. These *in vivo* toxicology



experiments prove that the small peptides described herein are of low toxicity to mammals and can be safely provided at large doses.

In further studies, the stability of small peptides in human blood and plasma was analyzed. The example below discloses these experiments.

#### EXAMPLE 7

5 This example describes several studies that were performed to access the stability of small peptides in human blood and plasma. Accordingly, human blood was taken freshly and treated with EDTA. Plasma was separated by centrifuging at 2,500 rpm for 20 minutes. GPG-NH<sub>2</sub> was added into blood or plasma at concentrations of 10mM or 50mM followed by incubation in 37°C for 1, 2 and 4 hours, respectively. As a control, GPG-NH<sub>2</sub> was  
10 added into RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, GIBCO), penicillin (100U/ml), streptomycin (100U/ml) and Polybrene (Sigma, 2µg/ml) and incubated in the same way. After incubation in 37°C, the GPG-NH<sub>2</sub> containing blood was centrifuged at 2,500 rpm for 20 minutes to isolate plasma. Some of the plasma samples were treated with CaCl<sub>2</sub> at concentration of 5 mM in 37°C for 10 minutes followed by centrifuging at 13,000 rpm for 30 minutes and the supernatant are referred to as CaCl<sub>2</sub> treated plasma. Then all the  
15 GPG-NH<sub>2</sub> containing plasma samples were diluted in RPMI medium to give the final concentrations 20 µM or 100µM of GPG-NH<sub>2</sub> (500 fold dilutions) and were then used in HIV-1 replication assays.

The replication assays were performed on HUT<sub>78</sub> cells and the HIV-1 SF-2 virus strain was used. Briefly, approximately 200,000 cells were resuspended in the diluted GPG-amide containing medium, plasma, or plasma from blood. The GPG-NH<sub>2</sub> containing medium, plasma, or plasma from blood was incubated with the cells for either 1hr,  
20 2hr, or 4hr at 37°C. Subsequently, SF-2 virus was added at 25 TCID<sub>50</sub>. After adsorption of 1 hour, cells were washed three times in RPMI medium then resuspended in the proper GPG-amide containing plasma and incubated at 37°C in 5% CO<sub>2</sub> with humidity. Culture supernatants were collected every four days and medium was changed until day 14 post infection. To monitor the replication of virus, HIV-1 p24 antigen protein in the supernatants was assayed using a commercially available kit (Abbott). The HIV-1 p24 assay was performed on the supernatants from day 7 and  
25 day 14 post infection. No significant difference in the ability to inhibit HIV-1 with GPG-NH<sub>2</sub> supplemented medium, plasma, or plasma from blood was observed.

The stability of GPG-NH<sub>2</sub> in human plasma was also assessed chemically by thin layer chromatography (TLC). (See Figure 7). In this experiment, <sup>14</sup>C GPG-NH<sub>2</sub> was incubated with human plasma at 37°C for 30 minutes, two hours, or eight hours and then the proteins were separated by TLC and were visualized by exposure of the  
30 chromatograph to autoradiography film. As shown in Figure 7 (lanes Hp0, Hp0.5, Hp2, and Hp8), a slight shift in mobility of the small peptide was observed. Although the mobility of the small peptide increased somewhat after 30 minutes of incubation in the human plasma at 37°C, no further change in mobility was observed at up to 8 hours. Mass-spectrometry analysis (electrospray analysis) of the TLC spots verified that all spots, including the spot with increased mobility, were GPG-NH<sub>2</sub>. The experiments above prove that the small peptides described herein are stable in  
35 human blood and plasma; they retain their antiviral properties, and are not degraded by plasma proteinases.

In the disclosure below, several studies on the adsorption, distribution, and metabolism of the small peptides are provided.

*Adsorption, distribution, and metabolism of small peptides*

Because an oral administration of a pharmaceutical comprising a small peptide is desired, the acid stability of small peptides was assessed by incubating  $^{14}\text{C}$ -labelled GPG-NH<sub>2</sub> in a solution of 50mM KCl and 0.1M HCl for various time periods. After acid hydrolysis, the radiolabeled tripeptide was analyzed by thin layer chromatography (TLC) and the HPTLC plate was developed with 25% methanol: 25%isopropanol: 15%butanol: 35% (0.1N HOAc and 0.1N NaOAc). As can be seen in Figure 8, incubation of the tripeptide for up to 24 hours did not affect the mobility, and hence not the molecular structure, of the GPG-NH<sub>2</sub>. This result established that small peptides survive acidic conditions similar to that found in the stomach.

Additionally, the *in vitro* uptake of small peptides from the culture medium into the cells was studied in a series of experiments. Accordingly, HUT<sub>78</sub>, Jurkat-tat III, and MT-2 cells were incubated with  $^{14}\text{C}$ -labelled GPG-NH<sub>2</sub> 165 nCi (equivalent to 0.7  $\mu\text{M}$  of GPG-NH<sub>2</sub>). An uptake of the small peptide was observed and between 8% (Jurkat-tat III cells) and 20% (HUT<sub>78</sub> cells) of the GPG-NH<sub>2</sub> was incorporated in the cells. This result proved that the incorporation of small peptides into several cell types was effective.

Further, the *in vivo* uptake of small peptides was analyzed in rats. Rats were fed  $^{14}\text{C}$  GPG-NH<sub>2</sub> and, after various time points, blood, urine, and tissue samples were collected from the animals. Samples of rat urine taken eight hours after feeding and rat plasma taken 30 minutes, two hours, and eight hours after feeding were separated on a TLC plate, as shown in Figure 7 (designated urine8, rp0.5, rp2, and rp8, accordingly). All the tissues were kept in -20°C after necropsy before any assay was performed. Ten to thirty micrograms of the tissue samples were collected from three different locations of each organ analyzed and the organ tissue was subsequently dissolved in 250  $\mu\text{l}$  of tissue solublizer (OptiSolv, LKB-Wallac) at 45°C for four to six hours. The homogenized tissue solutions were decolorized by the addition of 50  $\mu\text{l}$  of 30% H<sub>2</sub>O<sub>2</sub> and 100  $\mu\text{l}$  of isopropanol before 3 ml of 0.05M HCl acidified scintillation cocktail (Luma Gel, Lumac/3M) was added. The radioactivity was determined with a beta scintillation counter (LKB-Wallac 1218 Rack Beta). The free/unbound GPG-NH<sub>2</sub> in the plasma was collected by precipitation with one part of plasma and two parts of ethanol followed by incubation at -70°C for one hour and centrifugation at 20,000xg for 15 min at 4°C. Blood cell samples were diluted with PBS (in the ratio of 2 parts of blood cells to 1 part of PBS) before 10  $\mu\text{l}$  of the mixture was sampled and analyzed as the tissue samples. Five to 20  $\mu\text{l}$  of plasma and urine samples were directly mixed with 3ml of Ready Safe (Beckman) fluid before quantification. The results giving the distribution and the basis for calculation of maximum uptake are shown in Tables 10 and 11. The values are expressed in nCi.

TABLE 11

Animal number* nCi/ml or g tissue	1	2	3	4	5	avg
Brain	48	34	31	30.	33	35
Kidneys	450	491	467	446	477	466
Liver	599	413	454	507	503	495
Spleen	383	428	414	195	413	366
Thymus	366	288	290	338	372	331
Blood cells	90	81	99	95	101	93
Plasma	140	126	121	142	124	130
Urine	5,846	5,068	6,841	4,557	5,986	5,660
Total urine	7,016	7,096	3,284	283	2,395	4,015

\*Animals were sacrificed after 4 hours.

5

TABLE 12

Animal number*	6	7	8	9	10	avg
Brain	43	27	28	25	29	30
Kidneys	255	488	461	401	468	415
Liver	537	419	478	458	578	494
Spleen	307	281	257	336	285	293
Thymus	340	350	323	349	311	334
Blood cells	51	72	87	71	108	78
Plasma	138	123	135	129	148	135
Urine	2,992	5,040	3,121	4,297	2,175	3,525
Total urine	6,463	6,653	11,173	10,227	7,613	8,426

\*Animals sacrificed after 8 hours.

10

The calculation of the maximum uptake was determined as follows. The total feeding was 800 $\mu$ Ci/kg rat body weight (160  $\mu$ Ci in total per animal). On the assumption that the GPG-NH<sub>2</sub> and its metabolites were evenly distributed in the body, the GPG-NH<sub>2</sub> present in tissues would be the average counts/g from different tissues from the total number of animals studied divided by the total number of animals and multiplied by the body weight and the factor 0.9. This factor is derived to omit the blood volume since an estimate of blood volume is roughly 10% of the average body weight. For example (from the data of animals 1-5), if the total body weight for five rats was 207g and the radioactivity detected from various tissues was (35+466+495+366+331) or 1,693 nCi and the radioactivity detected from blood was (93+130) or 223 nCi and the radioactivity detected in urine was 4, 015 nCi, the maximal intake of the small peptide can be calculated as:

15

tissue:	$(35 + 466 + 495 + 366 + 331) / 5 \cdot 207 \cdot 0.9 = 63,240 \text{ nCi}$
fluids:	$\text{blood } (93 + 130) \cdot 207 \cdot 0.1 = 4,642 \text{ nCi}$
urine:	4,015 nCi
Sum:	$(63.24 + 4.642 + 4.015) / 800 \cdot 0.207 = 0.4342$ , or 43% maximal uptake

5

The relative distribution of retained/immobilized GPG-NH<sub>2</sub> and its metabolites in sampled tissues was observed to be highest in the liver followed by the kidney, followed by the spleen, followed by the thymus, followed by the brain. The radioactivity in the urine was observed to double between hours 4 and 8. Mass spectrometric data (electrospray mass spectrometry) of the urine radioactive spot from the TLC plate showed that only a small portion of the radioactivity in urine was intact GPG-NH<sub>2</sub>. (See Figure 7). The results from the *in vivo* studies above proved that a significant amount of small peptides are effectively delivered to blood, plasma, and several different tissues.

10

Additionally, as shown in Figures 9 and 10, a significant amount of small peptide remains in the plasma fraction over a long period of time. In Figure 9, the distribution of radioactivity between blood cells, plasma protein bound, as well as, non protein bound (free) plasma radioactivity is shown. The elimination of radioactivity from the plasma fraction is depicted in Figure 10. The tripeptide GPG-NH<sub>2</sub> has a half-life of 86.5 minutes. Protein bound radioactivity was assayed after precipitation with two parts of 99.5% ethanol. From the uptake and distribution data and the TLC data above, the minimal uptake of intact GPG-NH<sub>2</sub> recovered from the plasma was calculated and, in one hour after feeding of the rats, at least 1% of fed GPG-NH<sub>2</sub> could be recovered as protein free GPG-NH<sub>2</sub> in the plasma.

15

For the assessment of biologically active GPG-NH<sub>2</sub> in the plasma of animals fed the small peptide, plasma samples were prepared from blood obtained from the rats of the four week toxicology study the day after the last feeding. The plasma samples were diluted 1/5 in RPMI medium and were administered to PBMC infected with the SF162 strain of HIV-1, as described above. Viral infectivity was then monitored at seven, eleven, and fourteen days post infection by detecting the amount of p24 in the supernatant using a commercially available detection assay. (Abbott). As shown in Table 12, the sera obtained from the rats treated with the small peptide retained the ability to inhibit viral infectivity. In some cases, the administration of as little as 10 $\mu$ M GPG-NH<sub>2</sub> provided a sufficient concentration of small peptide in the plasma to enable the inhibition of HIV-1 replication. The percent reduction was calculated as in Table 6. The results from these experiments established that small peptides described herein can be maintained at concentrations in the body of an animal that are effective at inhibiting HIV replication.

20

25

30

TABLE 13

Animal #.	Feeding GPG (mg/ml)	p24 (pg/ml)	% reduction
Exp.1 day 7			
14	0	543.0	0
34	10	93.3	82.8
53	30	24.0	95.6
73	100	174.7	67.8
day 14			
14	0	22678	0
34	10	1636	92.8
53	30	938	95.9
73	100	9211	59.4
Exp.2 day 7			
16	0	321.8	0
36	10	219.2	31.9
56	30	194.3	39.6
76	100	173.5	46.1
day 14			
16	0	4075.4	0
36	10	4760.8	0
56	30	3574.4	12.3
76	100	2203.7	45.9
Exp.3 day			
18	0	183.9	0
38	10	255.6	0
58	30	107.3	41.7
78	100	96.9	47.3
day 14			
18	0	7578.4	0
38	10	6700.6	11.6
58	30	6893.0	9.1
78	100	7578.4	0
Exp.4 day 11			
13	0	242	0
33	10	170	29.8
52	30	487.4	0
71	100	51.7	78.6
Exp.5 day 7			
15	0	304.8	0
35	10	79.6	73.9
55	30	439.3	0
75	100	60	80.3

The proteins from whole plasma were also analyzed by column chromatography and fractionated and crude  
5 protein were separated by sodium dodecyl sulfate polyacrylamide gel (10%) electrophoresis (SDS/PAGE). Rat plasma

samples were partially purified with size exclusion (Sephacrose G-50, Pharmacia) chromatography (0.4x6cm), in a buffer of 10 mM Tris-HCl pH 8.3 and 50 mM KCl. Eluate was then separated by anionic exchange chromatography by using an increasing stepwise gradient of NaCl in a buffer of 10 mM Tris-HCl pH8.3 (Sephacrose CL-6B DEAE, 0.4x6cm). The eluate was monitored and pooled according to the radioactivity (Ready Safe, Beckman; LKB1218, Sweden). The protein fractions with strong signal were separated on a 10% SDS-PAGE and were subsequently blotted onto PVDF (polyvinylidene difluoride, BioRad) membrane before being subjected to Edman N-terminal amino acid sequencing (Applied Biosystems Procise Sequencer, USA).

As shown Figure 11, little radioactivity was observed to be covalently associated with proteins 60 minutes after feeding the animal. The proteins marked B1-B4 were sequenced and determined to be alpha-1 antitrypsin (B1), pentaxin (B-2), C-reactive protein (B-3), and B-4 could not be identified. These proteins are all synthesized in the liver. One interpretation is that hydrolyzed GPG-NH<sub>2</sub> was reutilized in the liver protein synthesis. These experiments established that small peptides are metabolized in the body and, since the identified associated protein (B-1, B-2, and B-3) are all synthesized in the liver, hydrolysis and reutilization of small peptides occurred in the liver.

Although the invention has been described with reference to certain embodiments and examples, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

22. The method of Claim 20 further comprising the step of administering an antiviral treatment selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.
23. The method of Claim 20, wherein the peptide is joined to a support.
- 5 24. The method of Claim 20, wherein the peptide is administered in a pharmaceutical comprising a pharmaceutically acceptable carrier.
25. A composition for inhibiting HIV replication in host cells comprising an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub> and wherein said composition inhibits HIV replication by interrupting assembly of the capsid.
- 10 26. The composition of Claim 25, wherein the peptide is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.
27. The composition of Claim 25, wherein  $X_3$  is glycine.
28. The composition of Claim 25, wherein said peptide in amide form has the formula  $X_4X_5X_1X_2X_3\text{-NH}_2$ ,  
15 wherein  $X_4$  and  $X_5$  are amino acids and wherein any one or two, amino acids is absent.
29. The composition of Claim 25, wherein the tripeptide  $X_1X_2X_3$  is found in the amino acid sequence of the capsid protein of HIV.
30. The composition of Claim 25, wherein the peptide is joined to a support.
31. The composition of Claim 25, wherein the peptide is incorporated into a pharmaceutical comprising  
20 a pharmaceutically acceptable carrier.
32. A method of inhibiting viral replication in host cells, comprising:  
administering to said cells an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>.
33. The method of Claim 32, wherein the peptide is selected from the group consisting of peptides  
25 having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.
34. The method of Claim 32, further comprising the step of administering an antiviral treatment selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors.
- 30 35. The method of Claim 32, wherein the peptide is joined to a support.
36. The method of Claim 32, wherein the peptide is administered in a pharmaceutical comprising a pharmaceutically acceptable carrier.
37. A method for interrupting viral capsid assembly comprising:  
contacting a cell with an effective amount of a peptide in amide form having the formula  $X_1X_2X_3\text{-NH}_2$ , wherein  $X_1$ ,  $X_2$ , and  $X_3$  are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>  
35

38. The method of Claim 37, wherein the peptide is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

39. The method of Claim 37, wherein X<sub>3</sub> is glycine.

5 40. The method of Claim 37, wherein said peptide in amide form has the formula X<sub>4</sub>X<sub>5</sub>X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>-NH<sub>2</sub>, wherein X<sub>4</sub> and X<sub>5</sub> are an amino acid and, wherein any one or two amino acids is absent.

41. The method of Claim 37, wherein the tripeptide X<sub>1</sub>X<sub>2</sub>X<sub>3</sub> is found in the amino acid sequence of a protein of the virus.

42. The method of Claim 37, wherein the peptide is joined to a support.

10 43. A method of identifying a peptide agent for incorporation into a anti-viral pharmaceutical comprising:

contacting with a plurality of cells infected with a virus with an effective amount of a peptide agent, wherein said peptide is not Gly-Pro-Gly-NH<sub>2</sub>;

analyzing the virus for incomplete capsid formation; and

15 15 selecting the peptide agent that induces incomplete capsid formation.

44. The method of Claim 43, wherein the analysis of capsid formation employs microscopy.

45. The method of Claim 43, wherein the virus is selected from the group consisting of HIV-1, HIV-2, and SIV.

20 46. The method of Claim 43, wherein the peptide agent is selected from the group consisting of a tripeptide, an oligopeptide, and a peptidomimetic.

47. The method of Claim 43, wherein the peptide agent is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

25 48. The method of Claim 43, wherein the peptide agent comprises an amino acid sequence that corresponds to an amino acid sequence of p24.

49. A method for identifying a peptide agent that binds to a viral protein comprising:

providing a viral protein;

contacting the viral protein with an effective amount of a peptide agent, wherein said peptide agent is not Gly-Pro-Gly-NH<sub>2</sub>; and

30 30 detecting the formation of a complex comprising the viral protein and the peptide agent.

50. The method of Claim 49, wherein the viral protein is from a virus selected from the group consisting of HIV-1, HIV-2, and SIV.

51. The method of Claim 50, wherein the peptide agent is selected from the group consisting of a tripeptide, an oligopeptide, and a peptidomimetic.



52. The method of Claim 50, wherein the peptide agent is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

53. A method of making a pharmaceutical comprising incorporating the peptide agent identified in  
5 Claim 49 in the pharmaceutical.

54. A method of making a pharmaceutical comprising:  
administering to a cell an effective amount of a peptide in amide form having the formula X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>-  
NH<sub>2</sub>, wherein X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>;  
detecting an inhibition of viral replication in the cell; and  
10 incorporating the peptide that causes inhibition of viral replication into the pharmaceutical.

55. The method of Claim 54, wherein the peptide is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

56. The method of Claim 54, further comprising the step of incorporating an antiviral compound  
15 selected from the group consisting of nucleoside analogue reverse transcriptase inhibitors, nucleotide analogue reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors into the pharmaceutical.

57. The method of Claim 54 further comprising the step of incorporating a carrier into the pharmaceutical.

20 58. A composition for inhibiting viral replication in host cells infected with a virus, comprising an effective amount of a peptide having the formula X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>R, wherein X<sub>1</sub>, X<sub>2</sub>, and X<sub>3</sub> are any amino acid and said peptide is not Gly-Pro-Gly-NH<sub>2</sub>, wherein R is a modulation group attached to the carboxy-terminus of said peptide and R comprises an amide group or other moiety having similar charge and steric bulk and wherein said composition inhibits viral replication by interrupting viral capsid assembly.


25 59. The composition of Claim 58, wherein the peptide is selected from the group consisting of peptides having the formula Gly-Lys-Gly-NH<sub>2</sub>, Arg-Gln-Gly-NH<sub>2</sub>, Cys-Gln-Gly-NH<sub>2</sub>, Lys-Gln-Gly-NH<sub>2</sub>, Ala-Leu-Gly-NH<sub>2</sub>, Gly-Val-Gly-NH<sub>2</sub>, Val-Gly-Gly-NH<sub>2</sub>, Ala-Ser-Gly-NH<sub>2</sub>, Ser-Leu-Gly-NH<sub>2</sub>, and Ser-Pro-Thr-NH<sub>2</sub>.

60. The composition of Claim 58, wherein X<sub>3</sub> is glycine.

61. The composition of Claim 58, wherein the peptide has the formula X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>X<sub>7</sub>X<sub>8</sub>X<sub>9</sub>X<sub>10</sub>X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>R,  
30 wherein X<sub>4</sub>, X<sub>5</sub>, X<sub>6</sub>, X<sub>7</sub>, X<sub>8</sub>, X<sub>9</sub>, and X<sub>10</sub> are any amino acid and wherein any one, two, three, four, five, six, or seven amino acids is absent, wherein R is a modulation group attached to the carboxy-terminus of said peptide and R comprises an amide group or other moiety having similar charge and steric bulk.

62. The composition of Claim 58, wherein the peptide X<sub>1</sub>X<sub>2</sub>X<sub>3</sub> is found in the amino acid sequence of the capsid protein of the virus.

1/10

**FIG. 1**

2/10





FIG. 2

3/10





FIG.3

4/10





FIG.4

HIV-1 SPTS-ILDIKQGPKEPFRDYVDRFYKTLRAEQA---SQEVKNWMTETLLVQNANPDCCKTILKALG--PAATLE-EMMTAC---QGVGGPGHK--ARVL// (SEQ. ID NO. 3)  
HIV-2 NPTN-ILDIKQGPKEPFSYVDRFYKSLRAEQT---DPAVKNNWMTQTLLIQNANPDCCKLVKGLG--MNPTLEEMLTAC---QGVGGPGQK--ARLM// (SEQ. ID NO 4)  
SIV NPVN-ILDIKQGPKEPFSYVDRFYKSLRAEQA---DPAVKNNWMTQTLLIQNANPDCCKLVKGLG--MNPTLEEMLTAC---QGVGGPGQK--ARLM// (SEQ. ID NO. 5)  
HTLV-1 DPS--WASILQGLEEPYHAFVERLNIALDNGLP---EGTPKDPILRSLAYSNANKECQKLLQARG--HTNSPLGDMRLR AC--Q-TWTPKDK--TKVL---// (SEQ. ID NO. 6)  
MPMV DPGASLTGVKQGPDEPFADFVHRLJTITAGRIFG---SAEAGVDYVVKQLAYENANPACQAAIRPYR--KKTDLTGYI LC--SDIGPSYQQGLAMA---// (SEQ. ID NO. 7)  
MMTV ---LAGLKQNEESYETISRLFEAVYRMMP---RGECSIL IKQLA WENAN SLCODLIRPIR--KTGTQDYI RAC--LDASPAV VQGMAY---// (SEQ. ID NO. 8)  
MMLV TN LAKVKGITQGPNESPSAFLERLKEAYRRYTPYDPEDPQEQETNVSMFHWQSA-PDIGRKLERLEDLRNKKTL-GDLVREA--ERIFNKR-----// (SEQ. ID NO. 9)  
RSV EPTDPWADIMQGPSESFVDFANRLJKAVEGSDL---P PSARAPVIIDCFRQKSQPDIOQLIRAAP-STLTPPGEIIKY VLDROKTAPLTDQGIAAAM// (SEQ ID NO. 10)  
MHR

FIG.5

6/10

14 DAYS POST INFECTION

**FIG. 6**

7/10




FIG.7



8/10






FIG.8

9/10

**FIG. 9****FIG. 10**

10/10




FIG.11

TABLE 1

*Amino Acid Sequence of Peptides Tested*

5	Leu-Lys-Ala (LKA)	Arg-Gln-Gly (RQG)
	Iso-Leu-Lys (ILK)	Lys-Gln-Gly (KQG)
	Gly-Pro-Gln (GPQ)	Ala-Leu-Gly (ALG)
	Gly-His-Lys (GHK)	Gly-Val-Gly (GVG)
	Gly-Lys-Gly (GKG)	Val-Gly-Gly (VGG)
10	Ala-Cys-Gln (ACQ)	Ala-Ser-Gly (ASG)
	Cys-Gln-Gly (CQG)	Ser-Leu-Gly (SLG)
	Ala-Arg-Val (ARV)	Ser-Pro-Thr (SPT)
	Lys-Ala-Arg (KAR)	Gly-Ala-Thr (GAT)
	His-Lys-Ala (HKA)	Lys-Ala-Leu (KAL)
15	Gly-Pro-Gly (GPG)	
	<i>Abbreviations Used:</i>	
	Leu-Leucine	Lys-Lysine
	Gln-Glutamine	Ala-Alanine
	His-Histidine	Ileu-Isoleucine
20	Cys-Cysteine	Gly-Glycine
	Pro-Proline	Arg-Arginine
	Val-Valine	Thr-Threonine
	Ser-Serine	

## EXAMPLE 1

25 In this example, the approaches used to obtain the small peptides listed above are disclosed. Several tripeptides were chemically synthesized with an automated peptide synthesizer (Syro, Multisyn tech, Tubingen, Germany). The synthesis was run using 9-fluorenylmethoxycarbonyl (fmoc) protected amino acids (Milligen, Bedford, MA) according to standard protocols. All peptides were lyophilized and then dissolved at the appropriate concentration in phosphate-buffered saline (PBS). The peptides were analyzed by reverse phase high performance liquid chromatography (RP-HPLC) using a PepS-15 C18 column (Pharmacia, Uppsala, Sweden).

30 In many embodiments, peptides having a modulation group attached to the carboxy-terminus of the peptide ("modified peptides") were used. In some cases, the modified peptides were created by substituting an amino group for the hydroxyl residue normally present at the terminal carboxyl group of a peptide. That is, instead of a terminal COOH, the peptides were synthesized to have CO-NH<sub>2</sub>. For example, preferred small peptides include glycyl-lysyl-glycine amide (GKG-NH<sub>2</sub>), cystyl-glutaminy-glycine amide (CQG-NH<sub>2</sub>), glycyl-prolyl-glycine amide (GPG-NH<sub>2</sub>), arginyl-

35

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number  
**WO 01/10456 A3**

(51) International Patent Classification<sup>7</sup>: A61K 38/06,  
C12Q 1/70, C07K 5/08, A61P 31/00, G01N 33/50, 33/569

(21) International Application Number: PCT/IB00/00961

(22) International Filing Date: 29 June 2000 (29.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/370,368 9 August 1999 (09.08.1999) US

(71) Applicant: TRIPEP AB [SE/SE]; Halsovägen 7, S-141 57  
Huddinge (SE).

(72) Inventor: VAHLNE, Anders; Wendelsvåg 4, S-436 50  
Hovås (SE).

(74) Agent: HERMANN, Gerhard; Vossius & Partner,  
Siebertstr. 4, D-81675 Munich (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility  
model), DK, DK (utility model), DM, DZ, EE, EE (utility  
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility  
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,  
TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
20 September 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/10456 A3**

(54) Title: PEPTIDES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF

(57) Abstract: The discovery of peptides in amide form that inhibit viral infection, including human immunodeficiency virus (HIV) infection is disclosed. Methods of use of peptides are also disclosed including use in medicaments for the treatment and prevention of viral infection, such as HIV infection.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/00961

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/06 C12Q1/70 C07K5/08 A61P31/00 G01N33/50  
G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 627 035 A (VAHLNE ANDERS ET AL) 6 May 1997 (1997-05-06)	1,3,7, 20,22, 24,25, 27,31, 32,34, 36,37, 39,54, 56-58,60
Y	* see cl.1, col.4, examples 4 and 5 *  --- -/--	1-3, 6-27, 30-39, 42,54-60

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

27 March 2001

Date of mailing of the international search report

06.04.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Gore, V

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/00961

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 872 210 A (MEDABALIMI JOHN L) 16 February 1999 (1999-02-16)	49,51,53
Y	* see col.3 lines 29-39 and 64-67, col.4 lines 50-59, col.5 lines 58-60, col.6 lines 38-49, col.9 lines 8-22 and example 6 *	1,3, 6-27, 30-39, 42-46, 54-60
X	WO 99 09056 A (UNIV MEDICINE AND DENTISTRY OF) 25 February 1999 (1999-02-25)	1,7,20, 22,24, 25,31, 32,34, 36,37, 54, 56-58,60
Y	* see pages 1 and 13, cl. 2-7 and 16-22 *	1-3, 6-27, 30-39, 42,54-60
X	WO 98 09985 A (EISENBACH SCHWARTZ MICHAL ;BESERMAN PIERRE (IL); YEDA RES & DEV (I) 12 March 1998 (1998-03-12) * see abstract, page 14 and cl. 3-7 *	1,3,7, 25,27,31
X	EP 0 421 074 A (PRODOTTI ANTIBIOTICI SPA) 10 April 1991 (1991-04-10) * see abstract and claim 10 *	1,7,25, 31
X	WO 98 35062 A (LINGAPPA JAISRI R ;LINGAPPA VISHWANATH R (US)) 13 August 1998 (1998-08-13)	43,44,46
Y	* see cl. 13-20 *	43-46
X,P	WO 00 09158 A (NEWCUMB WILLIAM W ;BROWN JAY C (US); UNIV VIRGINIA (US)) 24 February 2000 (2000-02-24) * see claim 1 *	43,46

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 00/00961

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 4-5, 28-29, 40-41, 61-62  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International Application No. PCT/IB 00 00961

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 20-24,32-39,42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Claims Nos.: 4-5,28-29,40-41,61-62

The scope of the claims is so broad that no meaningful search was possible. Although claims 4-5, 28-29, 40-41 and 61-62 are formally dependent claims, their scope is actually broader than the scope of the independent claims.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/IB 00 00961

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3,6-27,30-39,58-60

Tripeptides having the formula  $X1-X2-X3-NH_2$ , wherein  $X1$ ,  $X2$  and  $X3$  may be any aminoacid and wherein the tripeptide is not GPG- $NH_2$ . Pharamaceutical compositions comprising such tripeptides, their use as antiviral agents and possibly in vitro uses.

2. Claims: 43-57

Methods for screening antiviral peptides.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00961

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5627035 A	06-05-1997	AT 173934 T AU 667290 B AU 8433291 A BR 9106772 A CA 2088788 A DE 69130571 D DE 69130571 T DK 545991 T EP 0545991 A ES 2128322 T FI 930519 A GR 3029523 T HU 63177 A JP 3115596 B JP 6504035 T KR 220531 B MC 2306 A NO 930401 A OA 10051 A WO 9203147 A US 5346989 A	15-12-1998 21-03-1996 17-03-1992 20-07-1993 23-02-1992 14-01-1999 17-06-1999 16-08-1999 16-06-1993 16-05-1999 21-04-1993 30-06-1999 28-07-1993 11-12-2000 12-05-1994 01-10-1999 27-09-1993 17-02-1993 14-10-1996 05-03-1992 13-09-1994
US 5872210 A	16-02-1999	AU 7117496 A WO 9712907 A	28-04-1997 10-04-1997
WO 9909056 A	25-02-1999	AU 8912698 A	08-03-1999
WO 9809985 A	12-03-1998	US 6126939 A AU 4030097 A AU 4030197 A EP 0927190 A EP 0927191 A WO 9809984 A JP 2001500491 T JP 2001500492 T	03-10-2000 26-03-1998 26-03-1998 07-07-1999 07-07-1999 12-03-1998 16-01-2001 16-01-2001
EP 0421074 A	10-04-1991	IT 1231342 B DE 69018914 D DE 69018914 T ES 2071710 T JP 3090098 A PT 95112 A, B US 5182265 A	28-11-1991 01-06-1995 16-11-1995 01-07-1995 16-04-1991 18-04-1991 26-01-1993
WO 9835062 A	13-08-1998	NONE	
WO 0009158 A	24-02-2000	AU 5556799 A	06-03-2000